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ACHILLES: I know the rest of you won't believe this, but the answer to the question is 
staring us all in the face, hidden in the picture. It is simply one word- but what 
an important one: "MU"! 
CCRAB: I know the rest of you won't believe this, but the answer to the question is 
staring us all in the face, hidden in the picture. It is simply one word- but what 
an important one: "HOUSM"! 
[ ...... ] 
ANTEATER: I know the rest of you won't believe this, but the answer to the question 
is staring us all in the face, hidden in the picture. It is simply one word- but 
what an important one: "REDUCf!ONISM"! 
(DR Hofstadter, 
Gode~ Escher, Bach) 
Aan mijn ouders 
Voor Carla 
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CHAPTER 1 
INTRODUCTION AND OVERVIEW OF 1HE STUDIES 
Cystic fibrosis (CF) is the most common fatal autosomal recessive disease amongst 
Caucasians. The heterozygous carrier frequency has been esthnated to be approxima· 
tely 1:25, leading to 1:2500 live births affected with the disease. Children manifesting 
the disease were described at the beginning of this century, but the first publication of 
the ailment as a separate entity was in 1938 by Andersen. The major characteristic of 
the disease is the formation of abnormal exocrine gland secretions. The pancreas and 
the lung are the organs mainly affected. 
The basic defect of the disease has been elucidated, and involves a mutation in the 
gene encoding the CF transmembrane conductance regulator (CFrR). More than two 
hundred mutations have been described in the last few years, and additional ones are 
still being discovered. Most evidence points to a gene defect effecting a disfunction in 
the c1· channels of the exocrine glands. 
The diagnosis of the disease used to be based on the sweat test. A higb cr content of 
the sweat, due to a disfunction of the cr channels, ascertains the diagnosis cystic 
fibrosis. During recent years, other methods have become available. Both direct 
measurement of the channel function in vitro and DNA analysis are now used as 
complementary tests. 
Clinically, the disease is manifested by obstruction of the hollow organs by viscous 
secretions, leading to pancreatic insufficiency and chronic obstructive pulmonary 
disease. ln the lungs, the poor clearance of the viscous mucus promotes colonization 
and infection by micro-organisms, and bacterial lung infections determine the prog· 
4 Introduction and oveTView of the studies 
nosis for most CF patients. The decrease of lung function, due to destruction of lung 
tissue by infections, eventually leads to death at a relatively early age. 
The antibacterial tberapy of tbese recurrent infections is difficult for several reasons. 
Increasing resistaoce to antibiotics of the infectious organisms and host-bacterium 
interactions are among tbe major problems confronted by patients and physicians. 
Furtbermore, tbese patients display altered pharmacokinetics, characterized by an 
increased clearance for several antibiotics and otber drugs. Higher doses and more 
frequent dosing compared to non-CF patients are therefore often necessary. These 
problems are discussed extensively in Chapter 2. 
It has become clear from several studies, that tbe CF population is heterogeneous 
witb respect to tbeir pharmacokinetic parameters. Not only is tbere a large inter-
individual variation, also tbe intraindividual variation is considerable. For optimal 
treatment, for instance with drugs witb a narrow therapeutical index, individual drug 
monitoring is therefore necessary. In Chapter 3, individual drug monitoring is 
discussed witb special emphasis on CF patients. 
Thus, tbe Chapters 2 and 3 outline tbe major problems in the antibacterial treatment 
of CF patients. 
In tbe studies presented in this thesis, the problems encountered in antibacterial 
tberapy were approached from different angles; the objectives of tbe studies were 
tbreefold. 
The first objective concerns the emergence and prevalence of resistance to antibiotics 
of bacteria isolated from CF patients. Since CF patients are repeatedly treated witb 
antibiotics, emerging resistaoce is becoming, or is already, one of tbe major difficul-
ties in treating these patients. In Chapter 4, tbe focus is on Staphylococcus aureus. The 
resistaoce of S. aureus to several antibiotics was surveyed in strains isolated from CF 
patients. Furtbermore, tbe frequency of tolerant strains was evaluated. Tolerance is a 
type of resistaoce in which beta-Iactam antibiotics and in some cases vancomycin, 
inhibit growtb of the micro-organisms witbout killing tbem. It could be speculated 
tbat, due to repeated antimicrobial treatment of CF patients, tolerance of S. aureus is 
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induced, or tolerant strains are selected. In Chapter 5, the emergence of resistance in 
Pseudomonas aeruginosa is studied over a period of several years. Although an 
association between the use of antibiotics and increase of resistance bas been 
repeatedly observed in populations as a whole, few, if any data exist on individual 
patients. Since CF patients harbour the same strain for several years, it is possible to 
study emergence of resistance in the individual patient, and correlate this with 
antimicrobial treatment. Furthermore, to study the linkage between the emergence of 
resistance to different antibiotics, pattern analysis could be used. 
The second objective was to study the pharmacokinetics of beta-lactams duting 
continuous and intermittent infusion. As outlined above, an increase of resistance and 
altered pharmacokinetics both lead to treatment problems. Apart from the use of new 
antibiotics, improvement of existing therapy is necessary, for instance by optimization 
of dosing schedules. Studies in vitro and in animals suggest that, for beta-lactams, 
continuous infusion might be more efficacious than the usual regimen of three times 
daily. To study the pharmacokinetics of continuous versus intermittent infusion, these 
regimens were studied in volunteers and CF patients, and the results compared with 
each other. 
In Chapter 6 the pharmacokinetics of ceftazidime is described in human volunteers 
during intermittent and continuous infusion. To study the extent of tissue penetration 
of ceftazidime, suction blister fluid concentrations were also analyzed during these 
dosing regimens. Especially during intermittent infusion, the timing of the drawing of 
the blisters might be important for the concentration of ceftazidime in the blister 
fluid. This was examined by taking samples at different time-points. In Chapter 7, the 
pharmacokinetics and blister fluid penetration of meropenem was studied in human 
volunteers during intermittent and continuous infusion. Meropenem is a new car~ 
bapenem, with a potential use to treat pulmonary exacerbations due to P. aeruginosa 
in CF patients. 
As was discussed in Chapters 2 and 3, CF patients display altered pharmacokinetics to 
several drugs. For ceftazidime there are conflicting results, and studying phar-
macokinetics during continuous infusion may help to elucidate the origin of these 
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discrepancies. Also, if continuous infusion is to be used routinely, it is important to 
know the phannacokinetic behaviour of this drug under these circumstances. 
In Chapter 8, the pharmacokinetics of ceftazidime during continuous and intermittent 
infusion was studied in CF patients in a cross-over study, and the results are com-
pared with those of healthy volunteers. 
During the studies described in the Chapters 6, 7 and 8, there were indications that 
there may be a circadian rhythm in serum concentrations of ceftazidime and also of 
meropenem. An evaluation of these results is presented in Chapter 9. 
The third part of this thesis focuses on the interaction between P. aeruginosa and 
ceftazidime in vitro during continuous and intermittent infusion. As indicated above, 
continuous infusion may be more efficacious than intermittent infusion. However, few 
in vitro data exist where continuous infusion is compared with intermittent ad-
ministration. Determinations of the susceptibility of a nticro-organism, usually as a 
ntinimal inhibitory concentration (MIC) or a killing curve, do not take the fluctuation 
of antibiotic concentrations due to intermittent dosing into account, as usually occurs 
when patients are treated. 
The first part of Chapter 10 discusses this problem, and a brief review of the 
literature describing in vitro pharmacokinetic models is given. In the second part of 
this Chapter, an in vitro pharmacokinetic model is described, and the results of 
intermittent and continuous infusion of ceftazidime on the kiiiing of P. aeruginosa are 
presented. 
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CHAPTER2 
PRINCIPLES OF ANTIBACTERIAL THERAPY IN CYSTIC FIBROSIS 
INTRODUCTION 
Bacterial lung infections determine the prognosis for most cystic fibrosis (CF) 
patients. The antibacterial therapy is difficult, not only because of the special 
relationship which exists between host and bacterium, but also because the 
pharmacokinetics of antibiotics is abnormal in these patients. In this chapter these 
two features will be discussed in relation to antimicrobial therapy. First, pulmonary 
infection and its causative agents will be considered. In the second part new insights 
in the working mechanisms of antibiotics will be examined, which may lead to better 
treatment results. 
PULMONARY INFECTION 
The major cause of morbidity and mortality in patients with CF is pulmonary 
infection (Wood, Boat and Doershuk, 1976; Hoiby, 1982). When the disease was first 
described by Andersen (1938) most patients died at an early age. Since the 
introduction of antibiotics, the prognosis has improved dramatically and now many 
patients live into adulthood. Although this is not solely due to increasing use and 
efficacy of antibiotic treatroent, most clinicians think that antibiotics provide an 
important contribution to the treatment of CF patients when suffering from an 
infectious exacerbation. 
At birth, the lungs of CF patients are histologically normal or show only minor 
changes (Bedrossian et aL, 1976). Within the first year of life pathological changes 
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may develop, initially. in the bronchioles. Infection and hypersecretion of viscous 
mucus lead to peribronchiolar inflammation and small airway obstruction. This 
process may be accelerated by early vital infections (Abman et a!., 1988). As the 
disease progresses, the larger airways become involved and the various complications 
of bronchopneumonia, micro-abscess formation and bronchiectases develop. Chtonic 
airway obstruction results in a ventilation perfusion mismatch and hypoxemia, which 
may ultimately lead to pulmonary hypertension and cor pulmonale (Ryland and Reid, 
1975). 
In CF four bacterial species play an important role as infectious agents: Haemophilus 
influenzae, Staphylococcus aureus, Pseudomonas aeruginosa, and, on the American 
continent, Pseudomonas cepacia. Other organisms may also be present, but are relati-
vely infrequent (Hoiby, 1977; Petersen et a!., 1981; Thomassen, Demko and 
Doershuk, 1987). The pattern of isolation changes with the age of the patient. In the 
young, H. influenzae and S. aureus are isolated most frequently. With increasing age, 
P. aeruginosa is the most common organism cultured. Although there are several 
theories trying to explain this shift, none of these are satisfactory (Smith et a!., 1989). 
H. lnf/uenzae 
H. influenzae is probably the least harmful of these organisms. It is most often found 
in relatively young patients. If present, it is seldom cultured from sputum for more 
than a few months. In the majority of patients the sputum is free of H. influenzae 
after treatment. In a Danish study (Petersen et a!., 1981), 14% of acute exacerbations 
of respiratory symptoms were associated with H. influenzae. Most strains are biotype I 
and nonencapsulated (Hoiby and Kilian, 1976; Watson, Kerr and Hinks, 1985), but 
the reasons for this are not known. Recently, it has been demonstrated that H. 
influenzae is more often present in sputum then hitherto thought, especially when P. 
aeruginosa is present in large quantities. H. influenzae may then be difficult to detect 
due to overgrowth of P. aeruginosa (Terpstra et aL, 1988). Using monoclonal 
antibodies directed against an outer membrane protein and staining with in situ 
immuno-peroxidase in sputum smears, Moller et a!. (1992) showed that H. influenzae 
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was present in 54% of CF sputum samples, compared to 23% positivity with standard 
culture. However, the clinical significance of these findings still has to be resolved. 
S. ameus 
S. aureus was responsible for most of the lung morbidity and mortality when the 
disease was first described (Andersen, 1938; Huang et al., 1961; Iacocca, Van Loon 
and Banbere, 1961). Patients usually died at an early age. When penicillin was introd-
uced the prognosis of CF patients improved remarkably (Andersen, 1949). S. aureus is 
often held responsible for most of the early permanent lung damage. In a Danish 
study, 9% of the patients were colonized for more than 6 months (Szaff and Hoiby, 
1982), and persistent colonization and infection with identical types of S. aureus has 
been described (Goering et at., 1990). Since frequent and prolonged treatment with 
antimicrobial agents may lead to development of resistance and tolerance, we tested 
the activity of various antimicrobial agents against 52 S. aureus isolates from 52 
patients with CF, and investigated whether tolerance to methicillin was present. The 
results showed that, in general, the MICs of the drugs tested were within the 
therapeutic range, and that the proportion of tolerant strains was similar to that found 
for non-CF populations (Chapter 4). 
Although S. aureus is one of the predominant organisms isolated in CF patients 
during childhood, infections can usually be effectively treated with antibiotics. It has 
been speculated, however, that the lung damage caused by this micro-organism, or H. 
influenzae, predisposes to colonization with P. aeruginosa. 
P. aeruginosa 
Since the 1960's, a significant decrease in the frequency of isolation of S. aureus has 
been noted with an increase in P. aeruginosa (May and Hernick, 1972; Mearns, Hunt 
and Rushworth, 1972). This is probably due to relatively more patients reaching an 
older age, who later in life become colonized with P. aeruginosa. In the Erasmus 
University Hospital, the prevalence in 1988 was below 40% in children under 5 years 
of age, but amounted to 90% in the oldest age group (Figure 1). 
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There seems to be a relationship between the size of the treatment centre and 
percentage of patients colonized with P. aeruginosa. In larger centres, relatively more 
patients are colonized with this organism (Hoiby and Pedersen, 1989). The prevalence 
of patients with a chronic P. aeruginosa infection may be as higb as 70-80% (Isles et 
al., 1984). The role of treatment centres in acqniring P. aeruginosa, however, is not 
clear. If cross-infection occurs frequently, one would expect that often identical strains 
are isolated. Epidemiological typing showed that clusters of distinct strains could be 
found, indicating that cross-infection could have happened (Hoiby and Rosendal, 
1980; Speert and Campbell, 1987). In the Danish CF centre, the incidence of 
acquisition of P. aeruginosa decreased after the introduction of hygienic measures 
(Pedersen et al., 1987). Studies from holiday camps for patients with CF show that the 
risk of cross-infection is low (Speert, Lawton and Damrn, 1982). Siblings with CF 
sometimes carry the same strain, but this may be due to the same environmental 
source (Kelly et al., 1982). In the Erasmus University Hospital, the diversity of strains 
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Figure 1. Prevalence of P. aeruginosa in different age-groups of CF patients treated 
at the Erasmus University Hospital in 1988. 
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found, as determined by various methods of typing (Horrevorts et al., 1990; Chapter 
5), show no evidence of cross-infection being a widespread phenomenon. In con-
clusion, cross-infection probably does occur, but the frequency is very low (Hoiby and 
Pedersen, 1989). Once infection has occurred, it is almost impossible to eradicate the 
micro-organism and most patients harbour it for years. Whether repeated isolation is 
due to persistent colonization or reinfection with different strains was resolved by 
using different typing methods. Using a combination of conventional techniques, 
Horrevorts et al. (1990) showed that colonizing strains do as a rule persist for many 
years. The results of serotyping, pyocin typing and phage typing were consistent with 
each other. These results were later confirmed (Chapter 5), and new techniques such 
as restriction enzyme analysis and the use of probes showed similar results (Ogle et 
al., 1987; Grothues et al., 1988). 
It bas been observed that P. aeruginosa bacteria isolated from sputum in CF patients 
are often of the mucoid variety (Doggett, 1969). In many CF patients the initial strain 
is non-mucoid. When a transition to mucoid strains occurs, non-mucoid and mucoid 
strains may be isolated simultaneously, and gradually mucoid, alginate producing 
forms predominate (Doggett et al., 1964, Hoiby, 1974 ). The reason for and function of 
this are not exactly known. Recently, it was found that two potential conditions in the 
CF lung, high NaCl and dehydration, may have a profound influence initiating the 
production of alginate. The underlying molecular mechanism of the transition is 
beginning to be resolved (May et al., 1991; Russell et aL, 1992). 
There is still no explanation for the chronicity of the Pseudomonas infection. The 
basic defect of cystic fibrosis itself, for instance an altered epithelial cell surface 
favouring adherence of P. aeruginosa and other micro-organisms, could play a role 
(Boat and Cheng, 1983). The mucoid character and the production of alginate of P. 
aeruginosa, however, are often taken as a convincing explanation_ The formation of 
microcolonies (Lam et al., 1980) surrounded by alginate constitute an impregnable 
barrier for the phagocytes (Doring, Albus and Hoiby, 1988). The alginate layer may 
thus impair the ability of the immune system to combat P. aeruginosa in the CF lung. 
There is some evidence that the immune system is somehow involved in the impaired 
bacterial clearance of P. aeruginosa, although there is no evidence of a defect in host 
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immunity (Hoiby eta/., 1975; Doring eta/., 1988). Pier et al. (1987), however, showed 
a specific defect of opsonophagocytic antibodies to the mucoid exopolysaccharide in a 
group of CF patients colonized with P. aeruginosa when compared to noncolonized 
CF patients or healthy adults. It was suggested (Pedersen et al., 1989) that high titers 
of non-opsonic IgG subclasses might interfere with pulmonary macrophage phago-
cytosis or a change from opsonic to non-opsonic antibodies. The production of 
proteases which may cleave opsonizing antibodies, complement components and cell 
receptors on phagocytes (Suter, 1989; Doring, 1989), are probably also important. 
P. cepacia 
Since the early 1980's, P. cepacia has been recognized as a major pathogen in CF 
patients (Isles et a/., 1984; Thomassen et al., 1985), especially in adnlts. Initially 
isolated on the American continent only, the organism is now common in Europe as 
well (Simmonds et al., 1990). Three distinct clinical patterns can be observed: chronic 
aymptomatic carriage; progressive deterioration over many months with recurrent 
fever, progressive weight loss and repeated hospital admissions; and rapid, usual fatal 
deterioration in previously mildly affected patients (Isles et al., 1984). The virulence 
of the different strains seems to vary considerably, but little is known about the host 
immune response and pathophysiology of P. cepacia infection (Anonymous, 1992). 
Treatment of P. cepacia is often difficult, since the organism is intrinsically resistant 
to most antibiotics (Nelson et al., 1991). 
A cause of concern is cross-infection with P. cepacia. Although the transmission route 
remains a controversial issue (Nelson et al., 1991), cross-infection seems to be 
important (Lipuma et al., 1990). Since some strains may be very virulent, recommen-
dations with regard to prevention of cross-infection have been published, but the 
social impact of these guidelines will and can be hard to accept (Anonymus, 1992). 
Deterioration of lung function 
There is growing evidence that the formation of immune complexes, due to a vigorous 
response of the host to the chronic infection, and ineffective phagocytosis, possibly 
due to the formation of microcolonies, lead to an imbalance between polymorphic 
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mononuclear neutrophil proteinases and their inhibitors (Suter, 1989). This results in 
proteolytic and oxidative tissue damage (Elborn and Shale, 1990). The production of 
exoenzymes, such as elastase, by pseudomonas may also contribute to the 
pathogenesis (Woods and Schol, 1983). 
ANTIBIOTIC TREATMENT OF PULMONARY INFECTIONS IN CF 
Dosage 
The dosage of antibiotics in CF-patients is a controversial subject; few clinicians use 
the same amount of a drug for treatment (Michel, 1988). Often, dosages are based on 
in vitro Minimum Inhibitory Concentrations (MIC) and calculated as to obtain serum 
levels above MIC for most of the dosing interval, rather than based on the specific 
bactericidal effect of an antibiotic, or on the evaluation of clinical efficacy. Failure of 
therapy using conventional dosage regimens have lead to an increase in both dose 
and frequency of antimicrobial agents. There are several reasons why the usual 
dosage regimens may not be adequate: 
1. Different pharmacokinetics. The resorption and elimination of drugs in CF patients 
differ from those in non-CF patients. In general, CF patients have a larger volume of 
distribution and an increased total body clearance of beta-lactarns and arninoglycos-
ides (for reviews, see de Groot and Smith, 1987; Prandota, 1988; Spino, 1991) with, as 
a result, a smaller area under the curve (AUC), a shorter elimination half-time and 
lower peak plasma antibiotic concentrations. To obtain the same plasma concen-
trations as in non-CF patients, dosages have therefore to be increased. Since 
infections in CF are difficult to treat, drug monitoring in CF may be of particular 
importance to ensure an optimal dosing regimen (Chapter 3). 
2. Low sputum concentrations. Although the serum concentrations may be adequate, 
the site concentrations of the antibiotic may be too low. There are several factors 
influencing the penetration of the antibiotic in the bronchial secretions, which are 
mainly dependent on the barriers which the antibiotic has to cross within the lung 
(Bergogne-Berezin, 1981; Mendelman et a/., 1985; Honeybourne and Baldwin, 1992). 
Physico-chemical properties, degree of bronchial inflammation and route of admini-
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stration are all important. Inflammation has been shown to increase the permeability 
of the bronchial tissue to antibiotics. Because the inflammation in CF is mainly on the 
luminal side of the bronchi (Jeffery and Brain, 1988), penetration through the airway 
barrier may be hampered. 
In many antibiotics, the sputum concentration in relation to the plasma concentration 
is not known. Studies are complicated because of the large differences in the amount 
of sputum produced between and within patients, the variation in the rate of sputum 
expectoration, salivary contamination and medication (Honeyboume and Baldwin, 
1992). For aminoglycosides, sputum concentrations are substantially lower than 
plasma concentrations (Mendelman et al., 1985). Even when sputum concentrations 
are determined, it is not certain what this means for the concentration of antibiotic at 
the site of infection. 
3. Diminished activity of antibiotic in sputum. Since sputum or mucus contains mucins, 
proteins, DNA, lipid and cellular debris, these substances could interfere with the 
activity of the antibiotic in the sputum, for instance by binding. Ramphal et a/. (1988) 
did a binding study with standardized concentrations of macromolecules obtained 
from sputum of CF patients. Their results showed a decreased activity of tobramycin, 
but not of ceftazidime, which was probably due to increased binding of tobramycin. 
Differences in ion concentration and pH may also influence activity (Mendelman et 
al., 1985; Levy, 1986). 
4. Behaviour of micro-organism. P. aeruginosa in the CF lung form microcolonies (Lam 
et al., 1983; Govan and Harris, 1986) surrounded by a mucoid anion matrix. In vitro 
studies have shown that the penetration of antibiotics through this layer is hampered 
(Slack and Nicols, 1981; Nichols et al., 1988; Bolister et al., 1991). The alginate may 
thus function as a barrier to antibiotics, thereby rendering the micro-organism less 
susceptible (Govan and Fyfe, 1978; Slack and Nichols, 1981). However, the clinical 
significance of these findings is not exactly knowo (Bollister et al, 1991). 
5. Mixed bacterial populations. The P. aeruginosa bacterial population residing in the 
CF lung is not homogeneous, although belonging to the same strain. When a sputum 
sample is cultured, it is usually possible to isolate bacteria with different sensitivity 
patterns (Thomassen et al., 1979; Seale et al., 1979). 
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6. Emergence of resistance. As CF patients are often treated with antibiotics, emer-
gence of resistance during long-term use of antobiotics may occur. We studied the 
emergence of resistance of P. aeruginosa isolated from CF patients by comparing the 
Minimum Inhibitory Concentration for 15 antibiotics during two time-periods (Chap-
ter 5). From 34 chronically colonized patients, strains isolated before 1987 and in 
1990 or later were compared with each other. The pairs of strains showed similar 
typing patterns for each pair, indicating prolonged colonization with the same strain. 
Nineteen patients newly colonized in 1990 or later served as a control group. There 
was a marked increase in resistance between the 34 pairs of strains during the study 
period. The susceptibilities of the 34 strains isolated before 1987 were comparable to 
the strains of the control group. There was a significant correlation between the 
increase in resistance and the number of days spent in hospital and number of 
admissions to the hospitaL Pattern analysis of the emergence of resistance showed 
linkage within groups of antibiotics. It was concluded that long-term antimicrobial 
therapy is associated with development of resistance within the individual patient. 
Dosing schedules 
Discussion concerning the dosing regimens of antibiotic dmgs in general. especially 
the antinoglycosides and the beta-lactams, has been reopened during recent years (e.g. 
Cars and Craig, 1990). One of the reasons was the demonstration of the post-antibio-
tic effect (P AE), or lack thereof, of antibiotics on the killing and growth of bacteria 
(e.g. Vogelman and Craig, 1986). The PAE is the period of time which elapses before 
micro-organisms start to regrow when no longer exposed to an antibiotic, and differs 
for each class of antibiotics. Aminoglycosides have been shown to have a P AE on 
aerobic Gram-negative rods and Gram-positive cocci. Beta-lactams (excluding inti-
penem), on the other hand, show a PAE on Gram-positive cocci, but not on Gram-
negative rods, such as P. aeruginosa. 
Another important reason to reconsider dosing regimens is the presence or absence 
of a dose-effect relationship of an antibiotic. Since dosing regimens may directly 
influence the results of treatment, especially of the difficult to treat pseudomonas 
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infections in CF patients, these issues will be discussed more extensively for the 
aminoglycosides and beta-lactams. The quinolones are also considered. 
Aminoglycosides. The bactericidal effect and the PAE of aminoglycosides are concen-
tration dependent (Vogelman and Craig, 1986). Several studies have shown a corre-
lation between the peak plasma concentration of aminoglycosides one hour after 
administration and clinical and bacteriological response (Laskin et al., 1983; Rabin et 
al., 1980). However, the therapeutic range of aminoglycosides is narrow due to oto-
and nefrotoxicity (McRorie et al., 1989). The risk of side effects has been reported to 
increase if trough concentrations exceed a certain threshold (Jackson, 1983). These 
characteristics have lately resulted in less frequent dosing with higher dosages, and 
clinical trials are now in progress to demonstrate the efficacy and safety of these 
regimens. In CF patients, however, the situation may be different. After a conv-
entional dose, lower plasma concentrations and a shorter half-life are found than in 
the normal population, which could be explained by an increased total body clearance 
and larger volume of distribution or both (review: Spino, 1991). This may cause the 
dose interval to become too long. Horrevorts et al. (1987, 1988) therefore adjusted 
the dosing frequency in individual CF patients and obtained a significantly better 
clinical outcome than with a standard regimen when treating P. aerugi:nosa infections 
with tobramycin. Winnie et aL (1991) also found a 6-hour dosing interval more 
efficacious than an 8-hour interval in CF patients. The aim is to keep top levels 
between 6 and 12 mgfl, while trough levels should fall between 1 and 2 mg/1 
(Horrevorts eta/., 1987; Moore et aL, 1982). 
Beta-lactams. In contrast to aminoglycosides, a P AE of beta-lactams is absent when 
treating Gram-negative rod infections (excluding irnipenem). Killing of bacteria is 
time-dependent, but relatively independent of the concentration. Concentrations much 
higher than the MIC contribute no extra effect. The conventional treatment of three 
doses daily leads to plasma concentrations below MIC for part of the dosing interval 
and may then not be effective, while unnecessary high peak concentrations are 
reached after each dose. A continuous infusion overcomes this problem (Figure 2) 
and may lead to better clinical results, as has been shown in some reports (Daemen 
and de Vries-Hospers, 1988; David and Devlin, 1989). This is in agreement with stu-
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Figure 2 Simulated concentration-time curves of ceftazidime during continuous and 
intermittent infusion. With continuous infusion of 100 mg/kg/24 h, and a MIG of 8 
mg/1, a plasma concentration weU above MI C is reached continuouso/. Using 
intermittent dosing, the plasma concentration falls below MIG for about one third of 
the time (Based on data from De Groot and Smith, 1987). 
dies in laboratory animals (Roosendaal et a!., 1989). In CF patients, there is another 
argument in favour of a continuous mode of administration when treating P. aerugi-
nosa infections. In these patients, the elimination half-time is sometimes shoner than 
in non-CF subjects (de Groot and Smith, 1987; Spino, 1991), leading to a longer 
period of time below MIC when dosing intermittently; this subject is more extensively 
discussed in Chapter 8. Since beta-!actams do show a P AE on Gram-positive cocci, 
and these generally have a lower MIC, pulmonary exacerbations due to S. aureus may 
be treated using an intermittent dosing schedule. 
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Quinolones. Ciprofloxacin is one of the newer fluoroquinolones which is effective 
against P. aeruginosa. It has the advantage that it can be given orally, making home 
therapy feasible. Its bioavailability in CF patient was found to be 70% (Davis et al., 
1987) and 80% (Christensson et al., 1992), respectively. In the latter study, it was 
found that oral availability in CF patients was increased compared to healthy 
volunteers. Ciprofloxacin can be used as monotherapy, although this may be limited 
by the development ofresistance (Goldfarb et al., 1987). It is also effective against S. 
aureus and H. influenzae. 
Pharmacokinetic studies of ciprofloxacin in CF patients show conflicting results. LeBel 
et al. (1986) found a shorter half-life in CF patients compared to healthy controls, and 
advised a dosage given four times daily. Other studies (Davis et al., 1987; Stutman et 
al., 1987) showed no such differences. Both the tissue penetration and the sputum 
concentration were reported to be adequate, and with an MIC90 of 1 mgjl for P. 
aeruginosa, appropiate levels may be reached. 
The MIC of ciprofloxacin of P. aeruginosa often increases with a factor 4 to 16 during 
therapy (Bosso et al., 1989; Goldfarb et al., 1987; Rubio and Shapiro, 1986). Although 
usually reversible, resistance to this agent may become a problem in the future. 
Several trials have shown no difference in treatment results obtained with ciproflox-
acin compared to standard regimens (Bosso et al., 1987; Rubio and Shapiro, 1986). In 
one study the efficacy was slightly better (Hodson et al., 1987), although this may have 
been caused by the design of the study. In contrast, Jensen et al. (1987) showed that 
the long-term clinical effect of repeated courses of ciprofloxacin was inferior to that 
of conventional intravenous treatment. 
Of the newer quinolones, ofloxacin is increasingly being used. Resorption is close to 
100%, while for ciprofloxacin resorption is 70%-80%. However, the MICs of ofloxa-
cin for P. aeruginosa are at least a factor two higher (e.g. chapter 5; Gonzalez and 
Henwood, 1990). The somewhat higher resorption does not compensate for differen-
ces in MIC. Ciprofloxacin still appears to be the first choice among the fluoroqui-
nolones, although clinically good results have been obtained with ofloxacin (Jensen et 
al., 1987). 
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Aerosols 
Aerosolized antibiotics have been used since the 1940's. The aim is to deliver the 
drug within the intrapulmonary airways, so that effective local concentrations are 
obtained with low doses, and systemic side effects are avoided. Several trials have 
shown a beneficial effect (Hodson et a!., 1981; Steinkamp et a!., 1989). The number of 
acute hospital admissions may be reduced, wbich is advantageous socially as well as in 
terms of costs, although the aerosols are expensive. The administration, however, can 
be time-consuming, and most antibiotics have an unpleasant taste. It is unknown what 
quantity of the dose given is deposited in the lungs, and whether it reaches the 
infectious foci: in CF patients, the deposition of aerosol is non-uniform and most of 
the drug reaches the best ventilated areas (Laube et a!., 1989). 
Three points need further attention: firstly, inhaled antibiotics might lead to an 
increase in resistant organisms, but this has not been shown to be injurious (Hodson, 
1988; Steinkamp et a!., 1989). Secondly, hypersensitivity might be induced, hut has 
seldom been found. Bystanders, however, may suffer from hypersensitivity reactions 
when beta-Iactam aerosols are used. Lastly, hypertonic nebulized antibiotics may 
cause bronchoconstriction (Chua et a!., 1990). In the Danish CF Centre, a 
combination of colistin inhalation and ciprofloxacin orally resulted in a delay of onset 
of chronic P. aeruginosa infection (Valerius et a!., 1991). However, colistin inhalation 
therapy has been suggested to be a risk-factor in the acquisition of P. cepacia 
(Aoonymous, 1992). 
Indications for the use of aerosols are mild exacerbations which can be treated at 
home. Aerosols can also be used as maintenance treatment, preferably in com-
bination, or alternating, with another antibiotic such as ciprofloxacin. Maintenance 
treatment is sometimes necessary in patients with pseudomonas infections who need 
continuous suppression of their flora. 
An important issue when administering aerosols, is the use of the proper equipment 
and technique. A jet-nebulizer should be used to produce particles of 2-4 mum (Sterk 
et a!., 1984), preferably with a mouthpiece. The patient should be well instructed. In 
norntal lungs slow deep breathing results in a uniform deposition throughout the lung 
with limited aerosol depositon in the larger airways. 
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ANTIBIOTIC TREATMENT OF PULMONARY INFECTIONS IN CF: 
INDICATIONS AND CONSIDERATIONS 
Since CF patients are chronically colonized with micro-organisms, and bacteria more 
often cultured than not, it is not always easy to determine whether an infectious 
exacerbation is present. Many indices of an infectious exacerbation are used (Table I) 
but no consensus has been reached on which parameters should be employed to defi-
ne an exacerbation. Therefore, it is difficult to compare the results of clinical trials 
especially with regard to anti-pseudomonas therapy (Michel, 1988). 
Table l. Indices of infectious exacerbations 
Subjective parameters 
increase in cough 
increase in sputum production 
dyspnea 
malaise 
decrease in appetite 
Objective parameters 
lung function: decrease in FEVl 
weight loss 
pulmonary X-ray 
oxygen saturation 
sputum production 
bacterial counts in sputum 
infection markers in blood 
serology: number of precipitins 
(fcvc') 
Some variables, however, should be measured at regular intervals in order to follow 
the progression of the disease and could be used to decide whether antibacterial 
therapy is warranted, namely: lung function, in particular FEV1; weight; pulmonary 
X-ray and, in more advanced disease, oxygen tension and/or saturation and carbon-
dioxide tension. The number of precipitins against P. aeruginosa may be of value 
(Hoiby, 1977). 
Several markers in blood have been sought as indicators for an exacerbation, such as 
CRP. Generally, these markers can be important to describe the course of an 
exacerbation in the individual patient, but have limited value as a diagnostic tool. The 
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FEVl is the lung function parameter most often used when evaluating clinical trials 
and treatment, and was also used io the study descnoed io Chapter 8. However, at 
the end stage of the disease lung damage may be of such severity, that further 
deterioration is hardly possible; other indicators are then necessary. 
A decade ago, out-of-hospital treatroent of exacerbations due to H. influenzae and 
S.aureus was sometimes possible with oral medication, but antipseudomonal therapy 
was provided almost exclusively in the hospital. Since then, quinolones have become 
available, aerosol therapy at home has increased and, more recently home intra-
venous therapy has been introduced in several countries (Wiater et al., 1984; Kane et 
al., 1988; Bakker et al., 1992). These developments have diminished the sharp distinc-
tion that used to be made between an exacerbation due to P. aeruginosa to be treated 
in hospital and no exacerbation; however, the same priociples for treatroent should be 
used. After isolation and identification of the causing organism from sputum, its 
susceptibility for antibiotics should be tested. 
Table H. AntiOiotics commonly used to treat pulmonary exacerbations due to P. aeruginosa 
Drug 
Tobramycin 
in combination with 
Ticarcillin 
Cefta2idime 
Imipenem / cilastatin 
Aztreonam 
and/or 
ciprofloxacin: oral: 
intravenous: 
Dose 
10 mg/kg/day in three dosages, adjust after 
three days: peak 8-12 mgfl; trough 1·2mgfl 
intermittent 
administration 
mgfkg doses/day 
750 4 
150-200 3-4 
50·100 4 
150 4 
1500-2250 mg/ day in 3 doses 
400-800 mg/ day in 2 doses 
continuous 
administration 
mg/kg/24h 
500 
100 
100 
maximum 
daily dose 
(g) 
30 
12 
4 
8 
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Treatment should be started with high dosages of appropriate antibiotics (Table IT) 
and last for at least 14 days and until the lung function has returned to pre-
exacerbation level or has reached a plateau. The specific side effects of antibiotics 
used should be monitored. It is important that, when an exacerbation is treated with 
antibiotics, guidelines or a certain strategy be followed. 
This overview has served to show that many dilemmas still exist concerning anti-
microbial therapy. Whereas the choice of therapy is becoming more and more limited 
(Geddes, 1988) during the course of the disease, the agents still available should be 
handled in a rational manner and with great care. 
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CHAPTER3 
ABNORMAL PHARMACOKINETICS: THE NEED FOR MONITORING 
SUMMARY 
Optimal use of a drug depends on rational dosing and subsequent therapeutic drug 
monitoring for effectiveness and toxicity. Drug monitoring is not relevant for all 
drugs, but is indicated for drugs which have a narrow therapeutic range or show a 
large inter-individual variation. If the response is not satisfactory or toxic side effects 
are observed, the regimen has to be adjusted or another drug used. Methods have 
been developed to establish rational dosing schedules for the individual patient. In 
previous methods, patient's specific data such as age, length, weight and serum 
creatinine are integrated with population pharmacokinetic parameters for a drug. This 
approach is subject to an appreciable margin of error, particularly in patients whose 
physiology is far from normal. Therapeutic drug monitoring via blood level 
determination makes it possible to evaluate the patient's individual pharmacokinetic 
parameters on which a rational dosage regimen can be based. 
INTRODUCTION 
The list of available antimicrobial drugs is long and making the choice of an approp-
riate drug for therapy is far from simple. The establishment of a scientific basis for 
antimicrobial therapy is one of the most important developments in modern medicine, 
although substances with anti-infective potential have been used empirically for 
thousands of years (Majno, 1975). During the last forty years, better understanding of 
pharmacokinetics has made precise administration of drugs possible. This knowledge 
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is not always easy to apply to routine patient care. However, one aspect of clinical 
pharmacokinetics has become firmly established, namely therapeutic drug monitoring. 
This has been based on one, two or multiple compartment models, but model inde-
pendent pharmacokinetics axe becoming increasingly popular for that purpose. 
In choosing the appropriate drug, host as well as infecting organism factors must be 
considered. Optimal use of the chosen agent depends on rational dosing and sub-
sequent therapeutic monitoring for both effectiveness and toxicity. In the last decade 
it has been shown how important a dosage schedule can be as a determinant of ef-
ficacy and toxicity (Bakker-Woudenberg and Roosendaal, 1988; Mattie et al., 1988). 
For instance, the therapeutic activity of beta-lactam agents against gram-negative 
organisms depends upon sustained serum concentrations that axe in excess of the 
MIC rather than transient high peaks at intervals. On the other hand, axninoglycosides 
appear to be more toxic when given by continuous infusion, while their efficacy 
depends upon peak serum levels and the area under the curve, irrespective the 
method of administration, i.e. continuous or intermittent. 
Different methods have been developed to establish rational dosing schedules for the 
individual patient. These comprise a) nomograms and b) the use of pharmacokinetic 
(mainly one- or two-compartment) computer models. However, these methods axe 
limited in their application. Both are based on population kinetics and usually assume 
the volume of distribution to be a fixed fraction of the bodyweight, whereas between 
patients volume of distribution as fraction of the body weight can vary widely for a 
given drug (Zaske et al., 1982). In general, data for an individual patient such as age, 
sex, length, weight and serum creatinine axe integrated with the population pharmaco-
kinetic parameters for a drug. These axe used to calculate the dose or dosing interval 
necessary to reach desired concentrations. Sheiner and Beal (1982) have proposed an 
alternative system which is based on Bayesian statistics. Briefly, prior data on the 
population pharmacokinetic parameters is combined with that of the individual 
patient, including actual drug concentrations. Integration of these data can be used to 
predict volume of distribution and total body clearance for a particular patient. A 
rational dosage regimen can be based on these data. 
Chapter 3 35 
ABNORMAL PHARMACOKINETICS: TilE NEED FOR MONITORING 
General pharmacokinetic parameters of drugs are usually obtained from studies in 
healthy volunteers. However, in clinical practice drugs are often used in patients who 
are in poor health, for instance those with impaired absorption (whereby less of the 
administered drug is available), abnormal renal or liver function (whereby more or 
less of the drug will be excreted or metabolized), an altered serum protein content 
(whereby the fraction of free drug is decreased or increased) or an abnormal relative 
extracellular volume (as in ascites, oedema or dehydration and pregnancy). These 
could all influence the pharmacokinetics of the drug. Since pharmacokinetics deals 
with drug distribution and changes of drug concentration in the human body, any 
alteration in absorption, distribution, metabolism and elimination will result in 
abnormal pharmacokinetics. 
Drug monitoring, i.e. determination of the actual serum concentrations, is only of 
value when a meaningful relationship has been established between plasma levels and 
efficacy and/or toxicity. In particular, drugs with a low therapeutic index are 
ineffective if concentrations are too low, but toxic when levels are too high. Most 
clinicians are familiar with decreased drug elimination due to impaired renal function. 
We would like to focus attention on the individual patient with a larger volume of 
distribution and/or total body clearance and how these effect the pharmacokinetic 
profile of a particular drug. 
INCREASED TOTAL BODY CLEARANCE AND/OR VOLUME OF 
DISTRIBUTION 
The process of creating an appropriate dosage regimen should involve the admini-
stration of a loading dose followed by maintenance dosing. A loading dose is given in 
order to reach a desired level inunediately and should be considered whenever the 
half-life of the chosen drug is relatively long. The volume of distnlmtion is important 
when calculating the loading dose. Since volume of distribution and total body 
clearance determine the half-life, both are important for establishing the maintenance 
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dose. The volume of distribution is often expressed as a fixed percentage of the body 
weigbt and the total body clearance is derived from a putative relation with serum 
creatinine. These simplifications do not always reflect the real situation. 
When blood levels are plotted against time, a curve can be constructed from which 
the area under the curve (AUC) and the terminal elimination rate constant (B) are 
derived. These are then used for calculating total body clearance (TBC) and volume 
of distribution (Vd) by the following equations. 
TBC = Dose / AUC (1) 
Vd8 = TBC / B (2) 
An increased total body clearance leads to a smaller area under the curve which 
implies lower plasma concentrations. The elimination rate constant depends on total 
body clearance and volume of distribution according to equation 2. Since volume of 
distribution and total body clearance are independent variables, an increase in volume 
of distribution (TBC unchanged) results in a lowering of the elimination rate constant 
and therefore in an increase in half-life because this parameter is inversely related to 
the elimination rate constant. An increase in the volume of distribution could be 
present in patients with an increased extracellular volume, for instance patients with 
ascites. Patients with cystic fibrosis (CF) provide another example. The pharmaco-
kinetics of some antimicrobial agents appear to be different in these patients than in 
normal individuals (de Groot and Smith, 1987; Prandota, 1987; Prandota, 1988). Most 
studies repon an increase in total body clearance and/or volume of distribution. The 
total body clearance (Figure 1) and volume of distribution (Figure 2) of ceftazidime 
were shown to he increased in our cystic fibrosis patients as compared to healthy 
volunteers when these parameters were adjusted for body weigbt (Mouton et al., 
1990). The absolute values did not differ between the two groups, as did the 
elimination rate. Thus, patients with CF have a higber total body clearance and a 
larger volume of distribution per kg of body weigbt. The larger volume of distribution 
is probably due to an altered body mass composition. Moreover, there are wide va-
riations in pharmacokinetics between patients with CF, and even in the same patient 
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Figure I. Total body clearance of ceftazidime standardized to kg of body weight 
during continuous infusion in healthy volunteers and patients with cystic fibrosis 
(p<0.05) 
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Figure 2. Volume of distribution of ceftazidime standardized to kg of body weight 
during intermittent infusion in healthy volunteers and patients with cystic fibrosis 
(p<0.05). 
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at different stages of the disease for some but not all drugs. Consequently, the 
amount of drug required to successfully control an exacerbation varies from patient to 
patient and also in the individual patient during the course of the disease (Mann et 
al., 1985; Horrevorts et al., 1985). Therefore, most centres use serum concentrations 
as a basis for calculating a dosing regimen in order to achieve a better clinical 
outcome than is observed with conventional dosing schedules (Horrevorts et al., 1987; 
Winnie et al, 1991). 
When designing a rational dosing regimen for the individual patient, the pharmaco-
kinetic profile is of importance. Conventional nomograms or computer programmes, 
which are based on population pharmacokinetics, are therefore not always applicable 
to patients with an increased body clearance or volume of distribution. Individual 
pharmacokinetic parameters can be obtained by monitoring serum levels. 
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CHAPTER4 
SUSCEPTIBILITY TO VARIOUS ANTIMICROBIAL AGENTS AND TOLERANCE 
TO METHICILLIN OF STAPHYLOCOCCUS AUREUS ISOLATES 
FROM CYSTIC FIBROSIS PATIENTS 
Pseudomonas aeruginosa, Staphylococcus aureus and Haemophilus influenzae are the 
pathogenic bacterial species most frequently detected in the respiratory tract of 
patients with cystic fibrosis (CF). To minimize progression of pulmonary destruction, 
acute exacerbations in CF demand intensive antimicrobial chemotherapy (Mouton 
and Kerrebijn, 1990). Since persistent colonization and infection with identical types 
of S. aureus have been described (Goering et a!., 1990), frequent and prolonged 
treatment with various antimicrobial agents may influence resistance and tolerance in 
strains. Tolerance to penicillin has been proposed as one possible explanation for the 
poor response of some streptococcal infections to penicillin therapy (Goering et a!., 
1990). In this study we tested the activity of various antimicrobial agents against S. 
aureus isolates from patients with CF. In addition tolerance to methicillin in the 
isolates was investigated. 
Fifty-two isolates of S. aureus were recovered from sputum of 52 patients with CF. 
The strains were identified biochemically by means of the API-STAPH identification 
system anad stored at -70 •c until tested. Additional tests included a slide coagulase 
test, a catalase test and mannitol fermentation. Detection of beta-lactamases was 
performed as follows. Nitrocefin (0.1 ml) was placed in microdilution well and a 
bacterial suspension yielding 107 cfu/ml was added. Production of beta-lactamases 
was established if the solution turned a deep red within ten minutes. 
Antimicrobial agents were obtained as a standard laboratory powder from the 
manufacturers and stored and handeld as recommended. MICs were determined by 
an agar dilution technique. Freshly prepared serial twofold dilutions of antibiotic were 
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incorporated in Diagnostic Sensitivity Test agar (Oxoid, UK). Agar supplemented 
with 4% NaCI was used to define methicillin susceptibility (Jergens, 1986). Final 
concentrations ranged from 0.006 to 25.6 mg/1 (for penicillin up to 410 mg/1) Plates 
were inoculated with a multipoint inoculator, which delivered a final inoculum of 10" 
cfu per spot (1 1-'1 of liqnid) from overnight Mueller-Hinton broth (Oxoid) cultures 
adjusted to 10" cfu/ml using a barium silphate standard and diluted 10'1. Inoculated 
plates were incubated at 35 •c for 24 hours. The MIC was defmed as the lowest 
concentration of antimicrobial agent which inhibited visible growth. S. aureus strains 
ATCC 25923 and ATCC 29213 were included as control organisms in all sets of 
inoculations, and the MICs were consistent with established values within one twofold 
dilution. 
Tolerance to methicillin was determined using the gradient technique of Kim and 
Anthony (Kim and Anthony, 1983). Briefly, 40 ml of Mueller-Hinton agar (Difco) 
suplemented with 20 mg/1 methicillin was allowed to gel in a 15x15 15 em square 
petri dish which was placed at an angle to form a wedge. Once cooled, 60 ml of the 
same agar, but without antibiotics, was overlaid, and allowed to set on a level surface 
resulting in graduated concentrations nominally ranging from 0 to 20 mg/L Late-
logarithmic cultures were prepared and applied undiluted using cottom wool swabs. 
Up to six strains together with a non-tolerant and a tolerant control were inoculated 
as parallel streaks beginning at the lowest concentration along the axis of the 
gradient. As expected, there was no apparent growth after 24 hours and an impression 
of the surface was made using a sterile velvet pad which was applied to a methicillin -
free plate. This was incubated for 24 hours and the result growth was compared with 
that of the controls. Tolerance was defined as any growth which occurred beyond that 
of the non-tolerant control along the line of inoculation. The results are summarized 
in Table I and Table IT. Fourty-nine isolates produced beta-lactamases. The penicillin 
and methicillin MIC modes for these strains were 12.8 and 1.6 mg/1 respectively. 
Methicillin resistant strains of S. aureus were not found. On a weigbt basis imipenem 
and rifampicin were the most active of the agents tested, inhibiting 100% of the 
isolates at 0.025 mg/1 and 0.05 mg/1 respectively. At clinically attainable serum 
concentrations flucloxaciilin, cefamandole and cefuroxime had similar activity. 
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Table I. In vitro activity of penicillin against 52 isolates of Staphylococcus aureus obtained from 52 
patients with cystic fibrosis. 
Production of 
beta-lactamases 
Negative (n=3) 
Positive (n=49) 
Penicillin MIC (mg/l) 
Range 
0.05 
0.8-102.4 
Mode 
0.05 
12.8 
Methicillin MIC (mgjl) 
Range 
1.6-32 
0.8-12.8 
Mode 
1.6 
1.6 
Table II. In vitro activity of various antimicrobial agents against 52 isolates of Staphylococcus aureus 
obtained from 52 patients with cystic fibrosis. 
Antimicrobial Cumulative percentage of isolates inhibited at given 
agent concentration (mgjl) 
:50.006 0.012 0.025 0.05 0.1 0.2 0.4 0.8 1.6 32 2<6.4 
Flucloxacilin 13 73 100 
lmipenem 60 100 
Cefamandole 23 94 100 
Cefuroxime 6 27 100 
Gentamicin 2 2 10 96 100 
Erythromycin 2 10 96 96 96 98 98 100 
Clindamycin 2 12 96 98 98 98 98 98 100 
Rifampicin 8 87 100 
Fusidic acid 46 98 98 98 98 98 98 100 
Vancomycin 10 100 
Teicoplanin 4 13 100 
Ciprofloxacin 2 4 87 100 
Fleroxacin 6 98 100 
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With the exception of erythromycin, clindamycin and fusidic acid, MIC ranges were 
within one (imipenem, vancomycin) to four ( ciprofloxacin, gentamicin) twofold 
dilutions. However, it should be noted that the wider MIC ranges observed for 
erythromycin, clindamycin and fusidic acid were due to a single isolate. The gentami-
cin MIC for the 52 isolates was 0.4 mgjl or less. In general, MICs of the drugs tested 
were within the therapeutic range. Six strains (11.2%) appeared to be tolerant to 
methicillin. The proportion of tolerant strains identified in this study, i.e. 112%, is 
similar to that of 12.5% reponed by Goessens et al. (1984) in non-CF populations of 
S. aureus. We therefore conclude that frequent therapy in CF does not result in 
higher tolerance. Whether tolerance plays a role or not in the clinical outcome in CF 
has never been determined. Using the simple and reliable method described here it 
should be possible to determined this. 
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CHAPTERS 
EMERGENCE OF ANTIBIOTIC RESISTANCE AMONGST PSEUDOMONAS 
AERUGINOSA ISOLATES FROM PATIENTS WITII CYSTIC FffiROSIS 
SUMMARY 
We investigated the emergence of resistance to 15 anti-pseudomonal antibiotics 
amongst Pseudomonas aeruginosa isolates from 34 chronically colonized patients with 
cystic fibrosis by comparing the susceptibilities of strains isolated before 1987 and 
after 1989 from the same patients. Strains obtained after 1989 from a further 19 
patients who were newly colonized served as controls. 
The 34 pairs of isolates demonstrated a marked increase in resistance which could not 
be accounted for by a general increase during the intervening years since the 
susceptibility patterns of strains isolated before 1987 were similar to those of strains 
isolated from patients in the control group. There was a strong correlation between 
this increase in resistance and both the frequency of admissions to and the number of 
days spent in hospital. Cluster analysis of the changes in susceptibility for iodividual 
antibiotics revealed four distinct patterns of resistance: the fluoroquinolones with the 
exception of ofloxacin; the aminoglycosides; the ureidopenicillins and aztreonam; and 
the carbapenems, cephalosporins and carboxypenicillins as well as ofloxacin. 
We conclude thatlongterm administration of anti-pseudomonal antibiotics to patients 
who are chronically colonized with P. aeruginosa is associated with the development 
of resistance. 
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INTRODUCTION 
Pulmonary infection caused by Pseudomonas aeruginosa is one of the major causes of 
morbidity and mortality in cystic fibrosis (CF) patients, most of whom will receive 
antibiotics at least once a year (Wood, Boat and Doershuk, 1976; Hoiby, 1982). An 
association between the introduction and use of an antimicrobial agent and the 
subsequent emergence of resistant isolates has been demonstrated in several studies 
(Mouton, Glerum and Van Loenen, 1976; Cross, Opal and Kopecko, 1983; Levine et 
al., 1985; Courcot, Pinkas and Martin, 1989), including one of CF patients (Bosso, 
Allen and Matsen, 1989). However, since these data were based on populations of 
patients only a few, if any, of whom will have suffered relapses caused by the same 
organisms, such data cannot be extrapolated to the individual. As CF patients may be 
colonized with the same strain(s) for several years (Grothues et al., 1988; Horrevorts 
et al., 1990), they provide a unique opportunity to assess the impact of antimicrobial 
therapy both on the individual patient and on the population as a whole. We have 
therefore adopted an alternative approach for monitoring the emergence of resis-
tance by comparing the MICs of anti-pseudomonal antibiotics for P. aeruginosa 
strains isolated from 34 chronically-colonized patients during two time periods 
separated by at least three years. 
MATERIALS AND METHODS 
Patients. All CF patients were treated at the Erasmus University Hospital Rotterdam 
Dijkzigt. The 34 patients who made up the study population (group 34) bad a mean 
age of 19.6 years (range: 6-28) and had been admitted to hospital up to 28 occasions 
(median six) for a median duration of 114 days (range 0-590). 
During the study period patients were treated with a combination of ticarcillin and 
tobramycin, both administered intravenously, as frrst-line therapy (Mouton and 
Kerrebijn, 1990). Ceftazidime and ciprofloxacin were introduced in 1984 and 1986 
respectively, and were used as second-line agents. Aztreonarn, piperacillin, imipenem 
and amikacin, all of which were prescribed occasionally, were the only other anti-
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pseudomonal antiobiotics administered. 
Bacterial isolates. Since 1981, P. aeruginosa strains isolated from sputum of CF 
patients have been routinely stored at -70°C. Pairs of strains, one strain isolated from 
a specimen of sputum collected from each of the 34 patients in the study group 
before the end of 1986 (Group 34A) and the second from a specimen obtained from 
the same patients after 1 January 1990 (Group 34B) were recovered. The specimens 
had been collected either a the time of an out-patient visit or during an admission to 
hospital for an acute exacerbation, in both cases before intravenous therapy had been 
initiated. Strains of P. aeruginosa were also isolated after 1 january 1990 from the 
sputa of 19 newly colonized patients (group 19NC). If two or more morphologically 
distinct strains were identified in a specimen, only one, which was selected arbitrarily, 
was used for further study. 
Typing. The 34 pairs of strains of group 34 were characterized by serotyping and 
active pyocin typing as described by Horrevorts et al., (1990). 0-antisera were 
obtained from Diagnostics Pasteur (Marne-la-Coquette, France). 
Antibiotics. The following antibiotics were supplied as standard reference powders by 
their respective manufacturers: azlocillin and ciprofloxacin (Bayer); aztreonam 
(Squibb); amikacin and cefepim (Bristol-Meyers); cefpirome (Roussel); ceftazidirne 
(Glaxo); imipenem and norfloxacin (Merck, Sharp and Dome); meropenem (ICI); 
pefloxacin (Rhone Poulenc); piperacillin (Lederle); ofloxacin (Hoechst); tobramycin 
(Eli lilly); ticarcillin (Smith-Kline-Beecham). Stock solutions were prepared 
according to the recommendations of the National Committee for Clinical Laboratory 
Standards (NCCLS, 1990). 
MIC Determination. MIC's were determined by a standard agar dilution method 
(Sahm and Washington, 1991) as described previously (Horrevorts, 1989). Freshly-
prepared, serial two-fold dilutions of each antibiotic in concentrations ranging from 
0.03 to 2048 mg/1 were incorporated into DST agar ( Oxoid, Hampshire, England). 
Overnight Mueller-Hinton broth cultures of the isolates were adjusted to a turbidity 
equivalent to a 0.5 McFarland standard and an inoculum of 10'' CFU was delivered to 
the surface of the agar plates with a multipoint inoculator. The MIC was defined as 
the lowest concentration of each antibiotic which inhibited visible growth after 
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incubation for 18 h at 37°C. P. aeruginosa ATCC 27853 was included as a control with 
each batch; the MICs for this organism were required to be within one two-fold 
dilution of the reported values (NCCLS, 1990). 
Data analysis. The antibiotic concentrations inhibiting 25%, 50%, 75% and 90% of 
isolates in each of the three groups (34A, 34B and 19NC) were calculated from the 
MICs. The SAS CLUSTER procedure (SAS, 1990) was used to perform cluster 
analysis which made it possible to determine if a change in the susceptibilities of the 
Group 34 isolates to each of the 15 antibiotics was associated with changes in the 
susceptibilities to any of the other antibiotics over the same period of time. The MICs 
were therefore converted into logarithms and the resulting values for the strains 
belonging to each pair were substracted one from the other to yield the difference in 
susceptibility for each of the 15 antibiotics. Cluster analysis of these differences was 
performed according to Ward 's method with standardized values. 
To quantify the increase in resistance for each pair of isolates, the 15 differences in 
susceptibility were averaged to yield a resistance increase score. Spearman's rank 
correlation coeffficient was then used to determine whether there was a relationship 
between this score and the number of admissions to and duration of stay in hospital 
RESULTS 
Typing. Both of the strains which comprised 17 of the 34 pairs of isolates (1-17) 
belonged to the same serotype and pyocin type (Table I). For nine additional pairs 
(18-26), the serotypes of both strains were the same but one or both were non-typable 
by pyocin typing; minor differences in the serotypes of the strains which made up two 
of these pairs (25 and 26) were attributed to polyagglutinability. Conversely, the 
strains comprising five further pairs (27-31) shared the same pyocin type but one or 
both of the isolates which formed four of these pairs were non-typable by serotyping; 
the serotypes of the two strains which made up the fifth pair (31) were different. The 
strains comprising pair 32 were non-typable according to both typing methods and for 
pairs 33 and 34, the constituent strains belonged to different serotypes while one of 
the strains making up pair 33 and both strains making up pair 34 were non-typable by 
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pyocin typing. 
Susceptibility. The MIC:,s, MIC,S, MIC,5s and MIC,s for the three groups of 
isolates are shown in Table II. During the years which separated the two collection 
periods there was an increase in MICs of all 15 antibiotics for the Group 34 strains; 
the increase in the MIC,S varied from two- to 32-fold depending on the ann'biotic. 
The decline in susceptibility was uniform, as demonstrated by the concordance of the 
MIC:,s, MIC,s, MIC,s and the MIC,s. The Mic;,_,.s for the 34 strains isolated 
before 1987 (34A) were broadly similar to those for the control group (19NC), 
although the Mic;,_,.s of the aminoglycosides for the control strains more closely 
resembled those of the post-1989 isolates (34B). The high MIC,S of the quinolones 
for the control group resulted from the inclusion of two exceptonally resistant strains. 
Pattern analysis. Four distinct patterns of resistance were identified at the 0.1 level 
(Figure). Of these, the first two comprised the quinolones, with the exception of 
ofloxacin, and the aminoglycosides respectively. Aztreonam was grouped together with 
the ureidopenicillins, piperacillin and azlocillin, and the fourth cluster included the 
remaining antibiotics (the cephalosporins, the carboxypenicillin, ticarcillin, the 
carbapenems and ofloxacin). 
As results may vary according to the technique employed for performing cluster 
analysis, other procedures, including maximum likelihood analysis, were carried out 
for comparison. However, because the results obtained by the various methods were 
so similar, they have not been shown. 
Resistance increase score. The resistance increase scores were used to demonstrate 
that increase in antibiotic resistance of the 34 strains isolated from the study patients 
correlated significantly with both the number of hospital admissions (r;Q.498, 
p<0.0005) and the number of days spent in hospital (r;Q.573, p<0.0005). 
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Table L Typing results of 34 pairs of P. aeruglnosa strains isolated from 34 cbxonically colonized CF 
patients. 
Number isolate 1 (34A group) isolate 2 (34B group) 
before 1987 after 1989 
serotype pyocintype serotype pyocintype 
1 3/13 45c 3/13 45c 
2 13 45c 13 45c 
3 3 74c 3 74c 
4 3 46c 3 46c 
5 16 45c 16 45c 
6 15 74c 15 74c 
7 13 35b 13 35b 
8 6 45c 6 45c 
9 14 84b 14 84b 
10 1/3 78d 1/3 78d 
11 1/3/10 35b 1/3/10 35b 
12 6 84c 6 84c 
13 6 54c 6 54c 
14 8 74b 8 74b 
15 6 85c 6 85c 
16 3 85c 3 85c 
17 13 82d 13 82d 
18 11 lld 11 NT 
19 6 41d 6 NT 
20 13 NT 13 NT 
21 3 NT 3 NT 
22 13 NT 13 NT 
23 1/3 NT 1/3 NT 
24 1 NT 1 NT 
25 1/3 NT 1/10 NT 
26 1 NT 1/6 NT 
27 NT 34c NT 34c 
28 3 65c NT 65c 
29 NT 85c NT 85c 
30 3 74c NT 74c 
31 6 85c 5 85c 
32 NT NT NT NT 
33 6 66c 3 NT 
34 13 NT 16 NT 
Table 11. MICs of three sets of P. aemgirwsa isolates. 
antibiotic MICll MIC9J MIC,, MIC, 
34A 34B 19NC 34A 34B 19NC 34A 34B 19NC 34A 34B 19NC 
azlocillin 4 8 2 8 16 8 8 64 8 32 512 16 
piperacillin 2 8 I 4 8 4 8 32 4 8 64 16 
ticarcillin 8 16 4 16 64 16 32 256 32 64 512 64 
aztreonarn 2 4 1 4 8 4 8 32 8 16 32 32 
celipime I 2 1 I 4 2 4 32 4 8 32 8 
cefpirome 2 4 2 2 8 2 4 32 8 16 256 16 
ceftazidime 2 2 0.5 2 2 2 4 8 2 4 32 4 
imipcnem I 1 0.5 2 2 2 2 8 4 4 16 32 
meropenem 0.25 0.5 0.03 0.5 1 0.25 I 4 0.5 2 16 I 
ciprotloxacin 0.13 I 0.25 0.25 2 0.5 0.5 16 2 0.5 16 64 
nortloxacin 0.5 4 0.5 1 4 I 2 16 4 4 16 32 
otloxacin 2 8 2 2 8 2 4 16 8 8 32 32 
petloxacin 1 8 I 2 8 2 4 16 4 8 64 16 
amikacin 2 8 8 4 16 16 8 64 64 16 64 128 
tobramycin 0.5 1 1 0.5 2 2 I 8 4 2 16 64 I(') 
.§ 
& 
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Figure 1. Patterns of resistance to the 15 antibiotics for 34 pairs of P. aeruginosa 
isolates detennined by cluster analysis. The more closely the antibiotics are grouped 
together (e.g. noifloxacin and pejloxacin), the more closely they are related with 
respect to the emergence of resistance. 
DISCUSSION 
Exacerbations of pulmonary disease caused by P. aeruginosa occur frequently in CF 
patients. Treatment is made difficult for several reasons, not the least of which is the 
lack of consensus concerning optimal antimicrobial therapy (Geddes, 1988; Miche~ 
1988). Our practice is to administer a combination of antibiotics (Mouton and 
Kerrebijn, 1990) but since most patients are treated at least once a year (on up to 28 
occasions in the present study) resistance is an important consideration. 
The results of this study confirm that, with time the development of resistance to anti-
pseudomonal agents is inevitable in patients with CF. The data also suggest that this 
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resistance is directly related to the administration of antibiotics to individual patients, 
as opposed to a general increase in resistance in this patient population. The 
reduction in susceptibility of P. aeruginosa isolates applied to all of the antibiotics 
tested and resistance correlated significantly with both the number of admissions to 
and the duration of stay in hospital. However, the coefficients of correlation ap-
proximated 0.5, indicating that exposure to antibiotics in hospital only partially 
accounted for the increase in resistance; other factors, for instance the domiciliary use 
of antimicrobials may also play a role. 
The aminoglycosides did not follow the general trend observed for other antibiotics in 
that the MIC's of these agents for the strains in the control group resembled those for 
the organisms isolated from Group 34B patients in the latter phase of the stndy more 
closely than those for strains isolated in the earlier phase. Although we are unable to 
offer an explanation for this paradox, it cannot be accounted for by a general increase 
in the level of antibiotic resistance in our hospital. Nor can it be attributed to cross-
infection since CF patients tend to retain their own strains and a concurrent reduction 
in the susceptibility of the control isolates to other groups of antibiotics would have 
been expected if this had been the explanation. 
Virtnally all CF patients eventnally become colonized with strains of P. aeruginosa, 
which usually persist for long periods of time (Ogle et aL, 1987; Grothues et aL, 1988; 
Horrevorts et aL, 1990). Although morphologically distinct colonial types can be 
isolated from a specimen of sputnm sample, various typing methods have been used 
to demonstrate that they are often variants of a single strain. The use of sertyping and 
pyocin typing techniques in the present study have confirmed that the same strain 
may continue to colonize a patient for several years. 
In the course of examining specimens which yield multiple isolates, the selection of 
strains for further stndy may be arbitrary. In CF patients, this is further complicated 
by the fact that strains which are indistinguishable may subsequently produce 
morphologically variants with different susceptibility patterns (Seale et al., 1979; 
Thomassen et al., 1979). By selecting representative isolates on an arbitrarily basis 
there is the potential to underestimate the extent to which resistance has developed, 
particularly in patients who have received multiple courses of antibiotics. However, 
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this should not influence the outcome of cluster /pattern analysis. 
The emergence of resistance to antibiotics belonging to one or more unrelated groups 
has been described as a general phenomenon in CF patients (Bosso et al, 1989). We 
have made a sintilar observation, but the isolation of P. aeruginosa strains from the 
same patient allowed us to use pattern analysis on the changes in susceptibility of the 
15 antibiotics. It was anticipated that an increase in MICs of agents related by 
chemical structure and modes of action and degradation would have been clustered 
together and indeed, this was the case for the antinoglycosides and three of the four 
quinolones tested. However, aztreonam was found to be more closely related to the 
ureidopenicillins than to the cephalosporins, which themselves shared a common 
cluster with the carboxypenicillin ticarcillin and the carbapenems. Finding ofloxacin in 
the latter cluster, rather than with the other quinolones, was also unexpected. 
Ofloxacin was not available in our hospital during the study. The association between 
ofloxacin and intipenem could indicate cross-resistance between these drugs. A sintilar 
relationship between intipenem and ciprofloxacin ( quinolone-imipenem cross-resis-
tance) has been described previously (Aubert, Pozzetto and Dorche, 1992). In that 
report, in~vitro exposure of a strain of P. aeruginosa to ciprofloxacin and other 
fluoroquinolones selected quinolone- and imipenem-resistant variants but the 
converse, quinolone-imipenem cross-resistance after exposure to imipenem, was not 
detected. Resistance to several of the other antibiotics included amongst the 15 
agents tested was also noted although some of them had not been prescribed during 
the study period; this tends to support the theory that cross-resistance is the most 
likely explanation for this phenomenon. With the exception of ofloxacin, quinolone 
resistance occurred relatively independent of other groups of antibiotics. 
The results of the present study confirm that the efficacy of antibiotics in individual 
CF patients will be diminished with time. This limitation wil depend in part on the 
frequency with which these agents are administered. We conclude that P. aeruginosa 
strains in chronically-colonized CF patients remain fairly constant over long periods, 
and that repeated exposure to antibiotics during treatment for exacerbation of 
pulmonary disease and other unindentified factors are associated with the emergence 
of resistance in individual patients. Moreover, the development of resistance to 
Chapter 5 57 
antibiotics belonging to groups which are unrelated to !bose whicb tbe patient has 
received and to which tbe patient's own strain has not previously been exposed is a 
common occurrence. 
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CHAPTER6 
PHARMACOKINETICS OF CEFrAZIDIME IN SERUM AND SUCTION 
BUSTER FLUID DURING CONTINUOUS AND INTERMI'ITENT INFUSION 
IN HEALTIIY VOLUNTEERS 
SUMMARY 
The pharmacokinetics of ceftazidime were investigated during intermittent (IT) and 
continuous ( CI) infusion in 8 healthy male volunteers in a crossover fashion. The total 
daily dose was 75 mgjkg of body weight per 24 h in both regimens, given in three 
doses of 25 mg/kg/8 h (TI) or 60 mg/kg/24 h with 15 mg/kg as a loading dose (CI). 
After the third dose (TI) and during continuous infusion serum and blister fluid 
samples were taken. Seven new blisters were raised for each timed sample by a suc-
tion blister technique. Blisters took 90 min to form. Samples were then taken from 
four blisters (A samples) and one hour later were taken from the remaining three (B 
samples). The concentration of ceftazidime was determined using a HPLC method. 
After intermittent infusion the serum concentrations inttnediately after infusion (t=30 
min) and 8 h after the start of the infusion were 137.9 (standard deviation [sd] 27.5) 
and 4.0 (sd 0.7) mg/1, respectively. The half-life at "' phase (T1f2<>) was 9.6 min (sd 
4.6), T1f2S was 94.8 min (sd 5.4), area under the concentration-time curve (AUC) was 
285.4 mg.h/1 (sd, 22.7), total body clearance (TBC) was 0.115 liter/h.kg (sd, 0.022), 
and volume of distribution at steady state was 0.178 1/kg (sd, 0.023). The blister fluid 
(A) samples showed a decline in concentration parallel to the serum concentrations 
during the elimination phase with a ratio of 1:1. The Tv2 of the A samples was 96.4 
min (sd, 3.2). The concentration of ceftazidime in the B blister fluid samples was 
significantly higher (27%) than in the A samples over time. This shows that blisters 
may behave as a separate compartment, and establishes the need to raise new blisters 
for each timed sample. The mean AUC/h during continuous infusion was 21.3 mg.h/1 
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(sd 3.0). The TBC was 0.113 1/h.kg (sd O.Ql8), the urinary clearance 0.105 1/h • kg 
(sd 0.012) and the ceftazidime/creatinine clearance ratio was 0.885. The mean AUC 
of blister fluid per hour was 84.5% (18.0 mg.h/1; sd, 3.6) compared with that of 
serum. The A samples did not differ significantly from the B samples. The 
implications of continuous infusion of beta-lactams for treatment of serious infections 
are discussed. 
IN1RODUCTION 
Time-kill studies of beta-lactam antibiotics on aerobic Gram-negative rods show a 
bactericidal activity which is slow, proceeds with time and is maximal at relatively low 
concentrations (Vogelman and Craig, 1986). The killing is exclusively related to the 
time that serum and tissue levels exceed a certain threshold, whereas higher 
concentrations contribute no extra effect. When levels fall below this threshold, 
bacterial growth is immediately resumed. This interaction of beta-lactams with Gram-
negative rods has consequences for the way in which these drugs should be administe-
red. It has been shown, in experimental infections, that a continuous infusion of cef-
tazidime leads to better results than intermittent administration (Roosendaal et al., 
1989). This effect was most pronounced in severe infections. There are a few clinical 
reports that ceftazidime given as a continuous infusion may lead to a better outcome 
(Daemen and de Vries-Hospers, 1988). Since beta-lactam antibiotics are usually given 
intermittently, most pharmacokinetic data are based on this form of administration 
(De Klerk et al., 1983; Lebel et al., 1985; Lebel and Spino, 1988; Naber et al., 1983; 
Tjandramaga et al., 1982; Walstad et al., 1983; Warns et al., 1983; Wise et al., 1981). 
To smdy the pharmacokinetics of ceftazidime in serum and tissue fluid during 
continuous infusion, the pharmacokinetics of ceftazidime in eight volunteers were 
investigated in a crossover fashion during intermittent and continuous administration. 
Suction blister fluid samples were drawn as a measure of ceftazidime concentrations 
in tissue fluid. In addition, we investigated whether the concentration of ceftazidime 
in suction blister fluid is affected by the lifetime of the blister. 
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MATERIALS AND METHODS 
Volunteers. Eight healthy male volunteers, aged 20-29 years, participated in the study. 
Body weight ranged from 63-103 kg. Before entering the study, each volunteer 
underwent a complete physical examination and was screened biochemically (Na, K, 
urea, creatinin, alanine transaminase, aspartate transaminase, alkaline phosphatase, 
gamma g!utamyl transpeptidase, total protein, albumin, total bilirubin, and glucose) 
and haematologically (haemoglobin, haematocrit, packed cell volume, erythrocyte 
indices, leukocyte count, and platelet counts). A standard urine screening test was 
performed. The study was approved by the Medical Ethical Committee of the 
Erasmus University of Rotterdam and informed consent was obtained from each 
volunteer. 
Design. The pharmacokinetics of ceftazidime in each volunteer were studied during 
and after intermittent and continuous administration in a crossover fashion. For each 
volunteer, a minimum of four weeks was allowed to elapse between the two treatment 
regimens. 
Drug. Ceftazidime was kindly provided by Glaxo (The Netherlands). The drug was 
reconstituted according to the manufacturer's instructions and further diluted to 
obtain the necessary concentration for each volunteer. The total volume used 
amounted to 50 ml per dose for intermittent adntinistration. For continuous 
administration, the flow of the infuser was adjusted per individual to obtain the 
necessary dose per time-unit. 
Dosing. The total daily dose in both regimens amounted to 75 mg/kg of body weight. 
For intermittent adntinistration volunteers received 25 mg/kg every 8 h over 24 h. 
The infusion time was 25 min. For continuous adntinistration, 15 mg/kg was given as 
a loading dose (infusion time 25 min) and 60 mg/kg was given over 24 h with an 
infuser. 
Blood samples. Venous blood samples for ceftazidime assay were obtained from an 
indwelling needle from the opposite arm to that used for the infusion of the 
antibiotic. From subjects receiving intermittent infusion, samples were taken prior to 
the third dose {t;O) and at: 10, 20, 30, 40, 50 and 60 min and 15, 2, 4, 6 and 8 h 
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after the start of the third infusion. From subjects receiving continuous infusion, 
samples were taken prior to the start of the loading dose and continuous infusion 
(t=O) and also at 10, 20, 30, 40, 50, 60 min and 1.5, 2, 4, 8, 16, 20 and 24 h after the 
start of the infusions. 
After sampling, blood was allowed to clot on ice for 20 min, centrifuged and the 
serum was stored at -70° C until assayed. 
Blister fluid samples. Blisters were raised from the abdominal skin by the suction 
blister technique described by Kiistala and Mustakallio (1967). In brief: perspex cups 
containing 7 perforations with a diameter of 6 mm each, connected with a vacuum 
source, were used. The cups were placed on the skin and kept in place by applying a 
negative pressure of 300 mm Hg (400x16' Pa). Fifteen minutes after positioning the 
cups, the suction pressure was lowered to -225 mm Hg (-300x16' Pa). This pressure 
was maintained until 1.5 h after placing the cups; 7 full blisters, each containing 20-60 
1'1 of fluid, were formed by then. The flow of fluid into the newly formed blister 
occurred during the last 10-15 min of this 1.5 h period. Blister samples were drawn 
from four of the seven blisters, yielding a total sample volume of 50-150 I'L These 
samples were called the A samples. Two and a half hours after placement of the cup, 
samples from the remaining three blisters, the B sample, were drawn. Samples were 
stored at -70°C until assayed. 
The cups were placed at the following times: 1.5, 2.5, 4.5 and 6.5 h after the third 
infusion when dosing intermittently and 17.5, 18.5, 20.5 and 22.5 h after the start of 
the infusion continuous doses. 
Urine samples. Volunteers were encouraged to drink and urine samples were 
collected whenever possible, the volume of each void was measured and an aliquot of 
1 ml stored at -70° C until assayed to determine the urinary clearance. The urinary 
clearance during continuous administration was determined during the last 8 h of 
infusion. 
Analysis. Samples were assayed by a HPLC method, using an ODS column 
(Chrompack, Middelburg, The Netherlands) with a 0.05 M ammonium diphosphate 
solution (ph =2.0) containing 11.5% v fv acetonitrile as mobile phase. A perchloric 
acid solution, containing 50 mg/1 cefaclor as an internal standard, was added to an 
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equal volume of sample, centrifuged, and the supernatant was filtered through a 
membrane filter (Millipore Corp., type HV, 0-45 I'm). The lower limit of assay 
sensitivity was 0.5 mg/1. The between sample between day variation was less then 7%. 
All samples were assayed in duplicate. Control runs were performed regularly. 
Protein binding. Blister fluid samples of the 8 volunteers, obtained after intermittent 
administration, were pooled for each time point, yielding to four pooled "A" and four 
pooled "B" blister fluid samples. The serum samples were also pooled for the last four 
timed samples. In one part of each pooled sample the total ceftazidime concentration 
was determined as described above. In the remnant the non-protein bound 
ceftazidime concentration was determined using the Amicon micropartition system 
(MPS-1, 4010, Amicon, Mass. USA). Protein binding is expressed as 1 minus the ratio 
free ceftazidimejtotal ceftazidime • 100%. 
Other assays. A 24 h creatinin urinary clearance was performed on each study day to 
compare with the ceftazidime urinary clearance. 
Pharmacokinetic and statistical analysis. Serum concentrations were plotted versus 
time in a semilogarithmic plot. Pharmacokinetic parameters were estimated using the 
SAS NUN computer program package using a two-compartment open model with a 
weighted least squares adjustment (SAS Institute, Inc., 1982). The equations used 
were according to Allen et a!. (1982). The Wilcoxon matched pairs test was used to 
compare results between treatments (Snedecor and Cochran, 1980). Repeated 
measurements aualysis of variance from the BMDP 5V program package (University 
of California Press, 1988) was used to obtain the half-lives and to test the difference 
between A and B blister fluid samples. The concentration in blister 
fluid/ concentration in serum ratio of the A blister fluid samples during continuous 
infusion was determined from the area under the concentration-time curve (AUC) 
ratio during the time period at which the blister fluid concentrations were known, i.e. 
the last 5 h of infusion. 
The results are expressed as arithmetic means .±. standard deviations (sd), except for 
the half-lives which are expressed as harmonic means .±. sd. 
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Figure 1. Mean (.±_ sd) ceftazidime concentrations in serum and blister fluid plotted 
versus time after intermittent dosing (25 mg/kg per dose) 
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Figure 2 Mean ( + sd) ceftazidime concentrations in senun and blister fluid plotted 
versus time during continuous administration (60 mgjkg/24 h and 15 mg/kg as a 
loading dose) 
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Figure 3. Mean ( + sd) ceftazidime concentrations (plotted versus time) in serum 
and blisterfluid A and B samples during the elimination phase. 
RESULTS 
Concentrations in serum and blister fluid are plotted versus time in Figure 1 
(intermittent administration) and Figure 2 (continuous administration). Con-
centrations in blister fluid declined parallel to the concentrations in serum (Figure 1). 
The decline in concentration in the blisters is usually lagging slightly in time and the 
concentration itself was thus relatively higber at the same time point when compared 
with concentrations in serum. The penetration in tissue of less than 100% seems to 
compensate the time lag almost exactly. There might also be a very short time lag due 
to the mere drawing of the blisters. 
To determine whether ceftazidime diffuses freely between blisters and tissue, B blister 
samples were drawn 1 h after the original (A) samples from as-yet-intact blisters. 
After we tested that the time trend does not differ siguificantly between A and B blis-
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Table I. Pharmacokinetic parameters of ceftazidime after intermittent administration. 
Volunteer data 
No ~e Weight Length 
(years) (kg) (em) 
1 25 765 175 
2 24 103.5 190 
3 22 61.0 176 
4 28 815 182 
5 23 81.0 189 
6 21 73.0 183 
7 21 76.0 181 
8 25 74.0 182 
mean 23.6 783 1823 
sd 2.4 12.0 5.0 
see text for abbreviations 
Intermittent administration 
AUC TBC Vdss Blister /serum 
concentration 
(min) (min) (mg.h/1) (1/h-kg) (1/kg) (%) 
7.0 94.9 257.8 0.124 0.193 %.0 
123 928 273.4 0.158 0.178 139.8 
9.7 10Q.6 3139 O.OS1 0.180 80.8 
13.7 103.4 306.9 0.111 0.169 %.2 
17.7 94.8 2615 0.129 0215 115.2 
4.0 87.2 283.4 0.107 0.160 933 
62 88.7 3123 0.101 0.139 89.7 
6.1 95.8 274.0 0.113 0.193 1013 
9.6 94.8 285.4 0.115 0.178 1015 
4.6 5.4 22.7 0.022 0.023 183 
ter samples, the concentration of ceftazidime in the B blister samples was established 
to be 27% higher (95% confidence interval, 24% to 31%, repeated measurements 
analysis of variance) than in the A samples Figure 3. This may indicate that blisters 
behave as a separate compartment. 
Since protein binding ntight be responsible for the differences found between serum 
and blister fluid ceftazidime concentrations, this binding was measured in serum and 
blister fluid. Protein binding in serum was found to be 18.7% .±. 2.9%, and 14.9% .±. 
4.9% and 21.0% .±. 6.4% in the A and B blister fluid samples respectively. 
The concentration-time curve for serum after interntittent infusion showed a biphasic 
decline, representing a distribution phase and an elimination phase with mean half-
lives of 9.6 .±. 4.6 min at " phase and 94.8 .±. 5.4 min at B phase, respectively. The 
mean concentration in serum obtained immediately after infusion was 137.9 .±. 27.5 
mg/1, and the mean concentration at the end of the dosing interval was 4.0 .±. 0.7 
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Table n. Pharmacokinetic parameters of ceftazidime during continuous administration. 
volunteer TBC a.. CICC'It&Udio!c/ mean Blister AUC/ 
c~ serumAUC serum AUC 
no (lfh.kg) (1/h.kg) (%) (mg.hf!) (%) 
1 0.123 0.118 89.9 19.8 75.4 
2 0.094 0.086 92.9 24.0 85.0 
3 0.086 0.104 81.4 27.1 78.6 
4 0.135 0.121 89.0 18.4 76.4 
5 0.097 0.094 87.8 22.0 99.1 
6 0.120 0.098 84.4 19.8 86.0 
7 0.117 0.108 95.1 20.9 1023 
8 0.130 0.112 87.6 182 72.8 
mean 0.113 0.105 88.5 213 84.5 
sd 0.018 0.012 4.4 3.0 11.0 
see text for abbreviations 
mg/1. The mean AUC was 285.4 ± 22.7 mg.h/1, the total body clearance (TBC) was 
0.115 .±. 0.0221/h.kg and the volume of distribution at steady state was 0.178 .±. 0.023 
1/kg (Table I). 
The concentrations in blister fluid (A samples) showed a decline similar to that in 
serum with a mean half-life of 96.4 .±. 3.2 min (repeated measurements analysis of 
variance), and a blister fluidjserum concentration ratio of 101.5% .±. 18.3% during 
the elimination phase. 
Pharmacokinetic parameters obtained after continuous infusion are summarized in 
Table II. The TBC was 0.113 .±. 0.018 1/h.kg, the urinary clearance was 0.105 .±. 0.012 
1/h.kg during the last 8 h of infusion and tbe ratio ceftazidimefcreatinin clearance 
88.5% .±. 4.4%. The urinary clearance of the free fraction was 108.9% .±. 5.4, which is 
not significantly different from 100%, indicating that there is probably no net tubular 
handling of the drug. 
The mean AUC/h during continuous infusion was 21.3 mg.h/1 and the mean blister 
fluid AUC was 18.0 mg.h/~ corresponding to 84.5% of the serum (blister/serum). 
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There was no sigificant difference between A and B blister fluid concentrations 
during continuous infusion. 
The TBC during and after iotermittent administration was not significantly different 
from the TBC during continuous administration. 
DISCUSSION 
The aim of this study was to determioe pharmacokioetic parameters of ceftazidime 
during continuous infusion compared to iotermittent admioistration io serum and io 
tissue. As a representative of the concentration of ceftazidime io tissue, suction blister 
fluid concentrations were measured. Suction blisters were drawn as originally 
descnoed by Kiistala and Mustakallio (1967). Schreioer et a!. (1978) demonstrated its 
use for studies on extravascular antimicrobial activity. We used a modification of this 
techrtique by formiog new blisters before every sample to elimioate, as far as possible, 
a possible diffusion barrier between blister and tissue, and thus reduciog the time-lag 
of the concentrations io blisters versus tissue to almost zero during iotermittent ad-
mioistration. 
The penetration of ceftazidime in the blisters during intermittent infusion was 101% 
during the elimioation phase. This is in agreement with results of Wise eta! .. (1981), 
who found a penetration of nearly 100% usiog cantharide blisters. Walstad et a! .. 
(1983), who also used suction blisters, found a penetration of 80%. Investigators who 
used subcutaneous threads found lower values, i.e. 50% (Hoffstedt and Walder, 1981; 
Ryan et al, 1981). The difference between these values is rather high, and probably 
depends on the method used (Ryan et a!., 1982; Wise, 1986). The determioation of 
the penetration io blisters in steady state should be independent of the method used. 
We found a penetration of 84.5 %. This can not be explained by the protein binding, 
as the difference between the protein binding io serum··and blister fluid was found to 
be rather small. 
To study the effect of a possible diffusion barrier on the concentration of ceftazidime 
io the blisters, a second sample (B samples) was drawn 1 h after the first one (A 
samples) from the same set of, but other, blisters. If no diffusion barrier existed, the 
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concentrations in the second sample would equal those in serum as they did in the 
first drawings. In fact, they were 27% higher. This demonstrates that the blisters may 
bebave as a separate compartment and establishes the need to raise new suction 
blisters for each timed sample. This view is supported by a persistently high 
concentration of ceftazidime in blister fluid from one volunteer, drawn 2 and 3 h after 
the collection of the A blister samples (results not shown). The half-lives of 
ceftazidime are not significantly different in serum and the two blister samples, and 
are log-linear. In earlier studies, the time concentration curves in blisters seemed to 
be hi-exponential (Waistad et al., 1983). In these studies, the blisters were drawn at 
the onset of the study and the blisters from which the later samples were taken could 
have undergone histological changes and thus formed a diffusion barrier, explaining 
the relatively high concentrations found at the later time points. Also, the elintination 
of ceftazidime from the blisters is dependent on the volume of the blister with respect 
to the surface area. 
One possible explanation of the discrepancy between serum and blister fluid 
concentrations might be lower protein binding in the blister fluid samples due to a 
lower protein content of blister fluid (Vermeer et al., 1979). Although the protein 
binding in the A samples was slightly lower, this can not fully explain the differences 
found. Also, the higher values found in the B samples can not explain the relatively 
higher concentrations in the B samples. 
The pharmacokinetic data in serum obtained during intermittent administration are in 
agreement with earlier studies (De Klerk et al., 1983; Lebel et al., 1985; Naber et al., 
1983; Tjandramaga, 1982; Walstad et al., 1983; Warns et al., 1983; Wise et al., 1981) 
The data best fit a two-compartment open model. 
The bactericidal action of beta-lactam antibiotics on Gram-negative rods is related to 
the duration of exposure above a certain threshold (V ogelman and Craig, 1986). In 
conventional treatment regimens, beta-lactams are as a rule given intermittently. This 
may lead to plasma concentrations below this threshold during part of the dosing 
interval, and thus impair efficacy. In tissue, this effect may be even more marked, as 
antt'biotic concentrations in tissue are generally lower. During continuous infusion, a 
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level above this threshold may be easily maintained. A continuous infusion of 
ceftazidime has been shown to be more efficacious than intermittent administration in 
leucopenic animal models when treating Gram-negative rod infections (Roosendaal et 
al., 1989). A decrease in the dosing interval was shown to be more efficacious for 
ticarcillin (Gerber, 1983; Mordenti et al., 1985). In humans, there are a few reports 
that continuous infusion may lead to a better outcome. Daemen and de Vries-
Hospers (1988) were able to cure serious infections by P. aeruginosa with a 
continuous infusion of ceftazidime whereas the same drug had failed to do so when 
given intermittently. Bodey et al.. (1979) found that continuous;. infusion of 
cefamandole, administered together with carbenicillin, was more efficacious than 
intermittent infusion when treating febrile episodes in cancer patients. Since the 
antibiotic activity of ceftazidime on Gram-negative rods is related to the duration of 
active drug levels present at the site of infection, this should have consequences for 
the way in which ceftazidime, or any beta-lactam, should be administered. The 
present paper provides pharmacokinetic data which may serve as a model as to which 
doses should be applied. More clinical trials are needed to determine the efficacy of 
continuous dosing versus intermittent dosing in humans. 
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CHAPTER 7 
MEROPENEM PHARMACOKINETICS IN SERUM AND SUCfiON 
BUSTER FLUID DURING CONTINUOUS AND INTERMITI'ENT INFUSION 
SUMMARY 
The pharmacokinetics and penetration into suction blister fluid of meropenem was 
investigated after intermittent (10 mg/kg q6h) and during continuous infusion 
(10mg/kg/6h) in 8 healthy male volunteers in a crossover fashion. Concentrations in 
serum, urine and blister fluid were determined by a HPLC method. The pharmaco-
kinetic parameters in serum (.±.sd) T1128• AUC and clearance after the third dose of 
intermittent infusion were 62.7 (11.4) min, 43.5 (7.1) mg.h/1 and 292.1 (36.8) mljmin 
respectively. The penetration in blister fluid was rapid and good, with a AUC ratio 
blister fluid/serum of 84.7 (11.4) %. During continuous infusion, from 12h-18h after 
the start of the infusion, the mean concentration in serum was 63 (0.7) mg.h/1 and in 
blister fluid 87.1 (8.5) % thereof. The clearance was 3383 (45.6) ml/min for serum. 
Urinary recovery was 61.6 (8.7) % after intermittent and 61.9 (6.9) % after 
continuous infusion. 
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INIRODUCTION 
Meropenem is a new carbapenem with a good in vitro activity against a wide range of 
Gram-positive and Gram-negative bacteria, including P. aerugirwsa (Jones, Barry & 
Phillips, 1989; King, Boothman & Phillips, 1989; Moellering, Eliopoulos & Sen-
tocbnik, 1989). One of the advantages of meropenem in comparison with imipenem, 
is its relative stability to hydrolysis by the proximal mbular brush border enzyme 
dehydro-peptidase I (DHP-I). Thus it can be administered without an inhibitor of 
DHP-I, such as cilastatin. 
In earlier smdies, the pharmacokinetics of meropenem have been determined after a 
30 minute infusion (Bax et al., 1989; Burman et al., 1990). Meropenem penetration in 
to inflammatory exudate has also been examined (Wise et al., 1990). In this srudy, we 
have investigated the pharmacokinetics of meropenem at steady state, i.e. after three 
25 minute infusion doses, and during continuous infusion, in a crossover fashion. The 
penetration of meropenem into suction blister fluid (Mouton et al., 1990, Walstad et 
al., 1983) was also determined. 
METHODS 
Volunteers. Eight healthy male volunteers, aged 20-29 years, participated in the srudy. 
Their bodyweight ranged from 65-90 kg. Before entering the smdy, each volunteer 
underwent a complete physical examination and was screened biochemically (Na, K, 
urea, creatinine, AST, alkaline phosphatase, total protein, albumin, total bilirubin, 
glucose) and haematologically (haemoglobin, haematocrit, packed cell volume, red 
cell indices, leukocyte count, platelet count). A standard urine screening test was also 
performed. No drugs were used in the two weeks preceding the smdy. The srudy was 
approved by the Medical Ethical Committee of the Erasmus University of Rotterdam 
and written informed consent was obtained from each volunteer. 
Design. The pharmacokinetics of meropenem were smdied in each volunteer during 
and after intermittent and continuous administration in a randomized crossover 
fashion. In each volunteer a minimum of four weeks was allowed to elapse between 
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the two treatment regimens. 
Drug. Meropenem was provided by ICI Pharmaceuticals. The drug was reconstimted 
according to the manufacmrer's instructions. The flow of the infusor was adjusted per 
individual to obtain the necessary dose per time-unit. Infusion bags were changed 
every 3 hours during the continuous infusion. 
The dose solution concentrations were 20 mg/ml (30 mg/ml for one subject) for 
intermittent and 10 mg/ml for continuous infusion. 
Dosing. The total daily dose during both regimens amounted to 30 mg/kg. For the 
intermittent regimen volunteers received three doses of meropenem of 10 mg/kg per 
dose. Doses were administered at 0, 6 and 12 h. The infusion time of each dose was 
25 min. For the continuous infusion regimen, 0.2 mg/kg was given as a loading dose 
and 30 mg/kg was given over 18 h using an infusor. 
Dose concentration controls. Samples of the dose solutions were taken from each 
infusion bag of the third intermittent dose, and at the start and end of infusion of the 
fifth and the sixth infusion bag of the continuous infusion, i.e. spanning the period 12-
18 h. 
Blood samples. Venous blood samples for meropenem assay were obtained from an 
indwelling cannula from the arm opposite to that used for the infusion of the 
antibiotic. 
Intermittent: samples were taken: prior to the third dose (t=O) and at: 10, 20, 30, 40, 
50, 60 min and 15, 2, 2.5, 3, 4, 5, 6, 8, 10 and 12 h after the start of the third infusion. 
Continuous: samples were taken: prior to the stan of the loading dose and continuous 
infusion (t=O) and further at: 10, 20, 30, 40, 50, 60 min and 1.5, 2, 4, 8, 12, 14, 16, 18, 
19, 20, 22, 24 and 26 h after the start of the infusion. 
After sampling, blood was left on ice for 10 min, centrifuged at + 1 oc and the serum 
was rapidly frozen using an ethanol/dry ice mixture. Samples were stored at -70° C 
until assayed. 
Blister fluid samples. Blisters were raised from the abdominal skin by the suction 
blister technique as described earlier (Mouton et a!., 1990). In brief: perspex cups 
containing 3 perforations with a diameter of 6 mm each, connected with a vacuum 
source, were used. The cups were placed on the skin and kept in place by applying a 
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negative pressure of 300 mm Hg. Fifteen minutes after positioning the cups, the 
suction pressure was lowered to -225 mm Hg. This pressure was maintained until 15 
h after placing the cups. A total 60-200 .ul of fluid could be then drawn using a fine 
needle. Samples were rapidly frozen and stored at -7ff'C until assayed. 
The cups were placed at the following times: -1, -0.5, 0, 0.5, 1, 1.5, 2.5, 4.5 and 6.5 h 
after the start of third infusion when dosing intermittently and 2.5, 10.5, 12.5, 14.5, 
16.5, 185, 20.5, 22.5 and 24.5 h after the start of the infusion when dosing 
continuously. 
Urine samples. Urine samples were collected at the following times: 4, 8, 12, 14, 16, 
18, 20, 22, 24 and 26 h after the start of the infusion. The volume of each void was 
measured, an aliquot of 2 m1 rapidly frozen and stored at -70° C until assayed to 
determine the urinary clearance and recovery. The urinary clearance during conti-
nuous administration was determined during the last 6 h of infusion. 
Analysis. Samples were assayed by ICI Pharmaceuticals using an HPLC method (Bax 
et al., 1989). The lower limit of assay sensitivity was 0.18-0.45 mgjl for plasma, 0.15 
mg/1 for urine and for blister fluid 0.17 mg/1. The coefficient of variation for plasma 
was .5. 6% from 0.5-20 mg/1 and for urine .5. 5%. Blister fluid yielded the same linear 
response as plasma or urine. 
Other assays. A 24 h creatinine urinary clearance was performed on each study day 
to compare with the meropenem urinary clearance. 
Pharmacokinetic and statistical analysis. Serum concentrations were plotted versus 
time in a sentilogarithrnic plot. Pharmacokinetic parameters were estimated using the 
SAS NUN computer program package (SAS Institute, Inc., 1989) using a two-
comparttnent open model. The equations used were according to Allen et al. (1982). 
The Area Under the time-concentration Curve (AUC) after the third dose of 
intermittent infusion was determined using the log-linear trapezoideal rule with 
extrapolation to infinity. Blister fluid concentration/serum concentration ratio was 
determined from the AUC ratio. AUC, total body clearance (TBC) and urinary 
clearance during continuous infusion were determined during the time period 12-18 h. 
The Wilcoxon matched pairs test was used to test differences between treatments and 
between concentrations in the infusion bags. 
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Table I. Pbarmacokinetic parameters of meropenem after intermittent administration. 
Volunteer data Intermittent administration 
No Age Weight Length Tl/Za T,l"' AUC TBC Vdss Urinary 
recovery 
(years) (kg) (em) (min) (min) (mg.h/1) (ml/min) (!/kg) (%) 
1 24 80 194 11.7 74.4 42.7 312.0 0.325 732 
2 23 90 192 13.7 66.6 52.8 2843 0.261 73.6 
3 21 71 184 17.0 653 41.9 2823 0250 64.0 
4 29 80 184 63 51.0 53.6 248.6 0235 513 
5 26 72 175 17.0 63.2 45.7 262.7 0290 563 
6 25 76 182 6.6 44.6 34.8 363.6 0236 53.9 
7 23 68 188 23.7 78.5 41.7 272.0 0302 61.1 
8 20 65 187 20.4 57.5 34.8 311.5 0313 59.9 
mean 23.9 753 185.8 14.6 62.7 43.5 292.1 0276 61.6 
sd 2.9 8.0 6.0 6.2 11.4 7.1 36.8 0.036 8.7 
see text for abbreviations 
The results are expressed as arithmetic means .±. standard deviations (sd), except for 
the half-lives which are expressed as harmonic means .±. sd. 
RESULTS 
Concentrations in serum and blister fluid are plotted versus time in Figure 1 (inter-
ntittent administration) and Figure 2 (continuous adntinistration). As can be seen 
from the 0.5 h time point in Figure 1, the penetration of meropenem in blister fluid is 
rapid. Blister concentrations decline parallel to the serum concentrations during the 
first 4 hours. There seems to be a difference in concentrations at the 6 h sampling 
point. The mean serum concentration obtained immediately after interntittent 
infusion was 32.1 .±. 2.9 mg/1 and the mean concentration at the end of the dosing 
interval (i.e. 18h) was 0.61 .±. 0.15 mgjl. The mean AUC was 43.5 .±. 7.1 mg.hjl, the 
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Chapter 7 83 
Table II. Pharmacokinetic parameters of meropenem in blister fluid. 
Volunteer 
No 
1 
2 
3 
4 
5 
6 
7 
8 
mean 
sd 
Intermittent administration 
AUC 
(mg.h/1) 
34.8 
38.2 
33.0 
383 
41.4 
36.8 
353 
32.4 
363 
3.0 
Blister AUC/ 
Serum AUC 
(%) 
813 
72.4 
78.7 
71.4 
90.7 
1055 
84.7 
93.1 
84.7 
11.4 
see text for abbreviations 
Continuous infusion 
Mean blister fluid 
concentration 
(mgjl) 
4.6 
5.6 
4.8 
5.8 
5.8 
5.0 
6.7 
5.0 
5.4 
0.7 
Blister AUC/ 
SerumAUC 
(%) 
77.0 
82.8 
88.8 
102.2 
80.4 
80.9 
955 
89.0 
87.1 
85 
TBC 292.1 .±. 36.8 ml/rnin and the volume of distribution in steady state (Vdss) 0.276 
.±. 0.036 !/kg (Table I). The urinary recovery was 61.6 .±. 8.7 %. 
The blister fluid concentrations show a decline parallel to serum and the mean blister 
fluid/serum concentration (AUC) ratio was of 84.7 .±. 11.4% (Table ll). 
Pharmacokinetic parameters obtained after continuous infusion are summarized in 
Table ill. Continuous infusion at 30 mg/kg over 18 hours produced a steady state 
meropenem concentration of 6.3 .±. 0.7 mg/1. The TBC was 3383 .±. 45.6 ml/rnin, the 
urinary clearance was 209.0 .±. 35.4 ml/rnin during the last 6 h of infusion. The 
urinary recovery was 61.9 .±. 6.9 %. 
The mean blister fluid concentration during the last 6 h of continuous infusion was 
5.4 .±. 0.7 mg/~ corresponding to 87.1% of the serum (blister/serum, Table II). 
As also observed after the 25 minute infusion dose at the 6 h sampling point, there is 
a discrepancy between serum and blister fluid levels at the 22 h sampling point. The 
TBC and recovery during and after intermittent adrniuistration were not significantly 
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Table UL Pharmacokinetic.parameters of meropenem during continuous infusion. 
Volunteer TBC Cl,. a_,._; 
a_ 
No (mlfmm) (ml/mm) (%) 
1 369.7 26L7 148.2 
2 368.7 213.8 142.9 
3 3665 216.9 1313 
4 3935 25L3 1355 
5 279.8 1913 135.0 
6 3413 203.1 122.7 
7 267.7 1773 134.8 
8 319.2 156.4 108.4 
mean 3383 209.0 132.4 
sd 45.6 35.4 1123 
see text for abbreviations 
Table IV. Concentration control samples of meropcnem 
Infusion bag 
3rd intermittent infusion 
before 5th infusion 
after 5th infusion 
before 6th infusion 
after 6th infusion 
Mean concentration 
(mg/ml) 
19.4" 
9.9 
9.7 
10.2 
9.4 
• normalized from 30 mg/ml to 20 mgjml for one volunteer 
sd 
0.7 
0.4 
0.8 
03 
1.1 
Mean serum 
concentration 
(mg/1) 
6.0 
6.8 
5.4 
5.7 
7.2 
6.2 
7.1 
5.7 
63 
0.7 
different from the TBC and recovery during continuous administration. 
Urinary 
recovery 
(%) 
705 
57.4 
59.1 
63.9 
683 
60.9 
663 
49.1 
61.9 
6.9 
Control samples were taken of the third infusion dose of the intermittent admini-
stration and at the start and the end of the infusions from the fifth and the sixth 
infusion bags for the contiouous infusion io order to determioe stability of 
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meropenem under hospital conditions (Table IV). The deviation from the calculated 
20 mg/ml in the intermittent infusion bag was 3.2%, which is not statistically 
significant. For continuous infusion, the concentrations after the infusion were 4.8% 
lower than the before infusion values, but this is also not significant. During both 
treattnent regimens, no adverse effects were experienced by the volunteers, and no 
significant changes in biochemical or haematological parameters were found. 
DISCUSSION 
The pharmacokinetics of meropenem after intermittent dosing are generally in agree-
ment with earlier studies (Bax et al., 1989, Wise et al., 1990), and confirmed that 
meropenem may be administered without the need for an inhibitor of DHP-1. The 
recovery in urine was more comparable with the 65.4% found by Wise et al. (1990), 
than the 79% reported by Bax et al. (1989). The figure reported by Burman et al. 
(1990) amounted to 72%. The recovery after continuous infusion was also in the same 
range, 61.9%. There appears to be a large variation between subjects with regard to 
the meropenem recovery. This variation could be due to the extent of meropenem 
renal metabolism, as is suggested by the data of Burman et al. (1990). They found a 
strong negative correlation between recovery of the main metabolite of meropenern, 
ICI 213,689, and meropenem in urine. This phenomenon could not be explained by 
plasma pharmacokinetics. The meropenem urinary clearance was significantly larger 
than the clearance of creatinine, indicating tubular secretion. This has been confirmed 
by a probenicid interaction study in which renal clearance of meropenem was reduced 
by approximately one-third, to values compatible with glomerular filtration rates in 
normal healthy males. Co-administration of drugs competing for tubular excretion 
mechanisms, will probably have little value (Bax et al., 1989). 
The penetration of meropenem into suction blister fluid is rapid. The values found 
are comparable with those found for ceftazidime (Mouton et al., 1990, Walstad et al., 
1983) and slightly higher than for cefepime (Nye et al., 1989), but the penetration was 
slightly lower than found by Wise et al. (1990) for meropenem into inflammation 
blister fluid. However, the chemically elicited inflammatory reaction caused by 
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cantharidin results in blister fluid with a relatively high protein content, and higher 
antibiotic penetration ratios are generally found in these blisters compared to suction 
blisters (Wise, 1986). Also, as indicated in their discussion, their value of 110% may 
be influenced by a high value for one volunteer. The values for blister fluid 
penetration found in our study during intermittent and continuous infusion are 
comparable, 84.7% vs 87.1 %. After both intermittent and continuous administration 
of meropenem, the serum concentration of the later time points appeared higher than 
would be expected for the log-linear decline seen at previous times. This may 
represent a positive bias of the assay in serum at low concentrations, although a 
thorough review did not identify such a bias. Interestingly, the decline of the 
concentration in serum as depicted in the time-concentration plots in the reports of 
Wise et al. (1990) and Bax et a/. (1989) seems to indicate a similar trend below 1 
mg/1. This discrepancy at low concentrations may also be the cause of the relatively 
large errors found in the regression analysis when using a weighted procedure (results 
not shown). 
Meropenem exhibits good stability during typical hospital conditions. Even after three 
hours the decline in concentration was miuimal, and not statistically significant. If 
meropenem is given as a continuous infusion clinically, dose solutions in infusion bags 
could probably be used for periods greater than the 3 hours used in this study. 
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CHAPTERS 
PHARMACOKINETICS OF CEITAZIDIME DURING CONTINUOUS 
AND INTERMITIENT INFUSION IN ADULT 
CYSTIC FIBROSIS PATIENTS 
SUMMARY 
The pharmacokinetics of ceftazidime were investigated during intermittent (U) and 
continuous infusion (CI) in 9 Cystic Fibrosis (CF) patients (4 males and 5 females) 
during a pulmonary exacerbation due to P. aeruginosa in a crossover fashion. The 
total daily dose was 100 mg/kg/24 h in both regimens, given in three doses of 33.3 
mg/kg/8 h or 100 mg/kg/24 h. After at least two days of therapy serum samples 
were taken. The concentration of ceftazidime was determined using a HPLC method. 
The T1/2B was 1.53 h (sd 0.21), AUC 214.3 mg.h/1 (sd 45.3), Total Body Clearance 
(TBC) 149.2 ml/min (sd 37.2), the Vds 19.2 I (sd 4.2), the Mean Residence Time 1.98 
h (sd 0.19) and the urinary recovery 78.7 % (sd 11.1). The AUC during continuous 
infusion was 220.7 mg.h/1 (sd 30.3), the TBC was 140.0 ml/min (sd 35.9) and the 
urinary recovery 84.0 % (sd 6.1). The TBC (IT) was negatively correlated with the 
urinary recovery (U), and significantly lower than in healthy volunteers, as was the 
urinary recovery (CI). In contrast, the TBC during continuous infusion was sintilar to 
that fonnd in the volunteers, but significantly different when expressed per kg 
bodyweight. The serumconcentrations were relatively lower in the CF patients. 
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INTRODUCTION 
The major cause of morbidity and mortality in patients with cystic fibrosis (CF) is 
pulmonary infection (Wood, Boat and Doershuk, 1976). As patients grow older, most 
become chronically colonized with Pseudomonas aeruginosa, (Marks, 1981; Hoiby, 
1982). Pulmonary exacerbations due to this organism are difficult to treat, since the 
strains are often less susceptible or resistant to common antibiotics. Apart from tbe 
use of new effective antibiotics such as the quinolones, the dosage regimens of 
existing antimicrobial agents may be optimized. During the last decade, it has been 
shown bow important a dosage schedule can be as a determinant of efficacy and 
toxicity (Mattie, Craig and Pecbere, 1989; Cars and Craig, 1991). Time-kill smdies of 
beta-lactam antibiotics on P. aeruginosa show a bactericidal activity which is slow, and 
proceeds with time. There is no concentration dependent killing above the MIC 
(Vogelman and Craig, 1986). For beta-lactarns, tbe time above MIC ntay therefore be 
a determinant in clinical outcome (Scbentag, 1991). Animal smdies have shown that a 
continuous infusion of ceftazidime leads to a better efficacy as compared to 
ceftazidime given four times daily (Roosendaal et al., 1989). A similar observation 
was made for ticarcillin (Mordenti et al., 1985). It bas been suggested that continuous 
infusion of ceftazidime may lead to a better clinical outcome as compared to tbe 
usual regime of 3·4 times daily administration when treating pulmonary exacerbations 
in CF patients caused by P. aeruginosa (Mouton and Kerrebijn, 1990), especially so 
since it has been suggested by several authors that the elimination of antibiotics in CF 
is enhanced as compared to non-CF individuals (Spino, 1991). As part of a larger 
clinical smdy, tbe pharmacokinetics of ceftazidime were determined during continuous 
and intermittent infusion in a randomized cross-over fashion, and the results are 
compared with healthy volunteers (Mouton et al., 1990). 
MATERIALS AND METHODS 
Patients. CF patients treated at the Erasmus University Hospital Dijkzigt Rotterdam 
were eligible for the smdy. Inclusion criteria were pulmonary exacerbation due to P. 
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aeruginosa, sensitivity of P. aeruginosa to ceftazidime and decline of FEV1 of more 
than 10% as compared to base-line values for each individual patient as measured 
between exacerbations. The study was approved by the Medical Ethical Committee of 
the University Hospital Dijkzigt, Erasmus University of Rotterdam and informed 
consent was obtained from each patient. 
Design. The pharmacokinetics of ceftazidime were studied in each patient during 
interntittent and continuous administration in a randomized cross-over fashion during 
two pulmonary exacerbations due to P. aeruginosa. The mean duration between 
exacerbations was 259 days (range: 74-515 days). 
Drug. Ceftazidime was used as its commercial preparation. The drug was 
reconstituted according to manufacturer's instructions. 
Dosing. The total daily dose amounted to 100 mg/kg. For interntittent administration, 
patients received 33.3 mg/kg per dose every 8h. The infusion time was 30 min. For 
continuous administration, 100 mg/kg was given over 24 h with an infusor. 
Blood samples. Venous blood samples for ceftazidime assay were taken after at least 
2 days therapy and obtained from an indwelling cannula from the arm opposite to 
that used for the infusion of the antibiotic, or from capillary puncture. Samples were 
drawn at the following time points: For interntittent administration prior to the dose 
(t~O, 8.00 am) and at: 30, 40, 50, 60 min and 1.5, 2.5, 4, 6 and 8 h after the start of 
the infusion; for continuous infusion at t~O (8.00 am) and at 2, 4, 6, 8 h. A control 
sample was taken the previous day at 12.00 am. After sampling, blood was left on ice 
for 20 min, centrifuged and the serum was stored at -70° C until assayed. 
Urine samples. Urine samples were collected between 8.00 am and 4.00 pm. Before 
dosing, at 8.00 am aswell as at 4.00 pm, the patients were asked to void. 
Analysis. Samples were assayed by an HPLC method as described before (Mouton et 
a/., 1990). 
Pharmacokinetic and statistical analysis. The SA$ program (SAS, 1990) was used to 
analyze the results. Pharmacokinetic parameters were estimated using the SAS NUN 
procedure with a two-compartment open model with a weighted least squares 
adjustment, with the exception of subjects 1, 2 and 6 for which a one-compartment 
model was used (Yamaoka, Nakagawa and Uno, 1978). Equations used were those as 
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Figure I. Mean ( + sd) serum concentrations of ceftazidime plotted against time 
during continuous administration (100 mg/kg/24/z). A control sample was taken the 
day before at 12.00 a.m. 
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Figure 2. Mean (.±. sd) serum concentrations of ceftazidime plotted against time 
during intermittent administration (33.3 mg/kgjdose). 
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described by Allen et al. (1982). The Area Under the time-concentration Curve 
(AUC) was determined using the trapezoideal rule. AUC, Total Body Clearance 
(TBC), Mean Residence Time (MRT), Volume of distribution (Vd8 and urinary 
recovery were determined during the time-period 8.00 am to 4.00 pm. The Body Mass 
Index (BMI) was calculated as weigbt/length2• The Lean Body Mass was calculated as 
described by Hallynck et al. (1981). The Wilcoxon matched pairs test was used to test 
differences between treatments, and the Mann-Whitney test was used to test 
differences between groups. For correlation analysis, the Spearman correlation 
coefficient was used. 
Volunteers. To compare data with those of healthy volunteers (mean age 23.6 .±. 2.4 
years, mean weight 783 .±. 12 kg, Mouton et al., 1990), the AUC and TBC after 
intermittent infusion of the latter group was recalculated over the same time-period 
(i.e. 0-8 h) as the CF group using corresponding time-points. 
Since the CF group consisted of both males and females, we analyzed the data 
separately for the males aswell. For the non-standardized results, only the males were 
used to compare with the volunteers. 
RESULTS 
From nine CF patients pharmacokinetic data were obtained during intermittent (TI) 
and continuous infusion (CI). Patient characteristics are summarized in Table I. Five 
patients received intermittent infusion and four continuous infusion during the first 
episode. The FEV1 and bodyweigbt at admission were not significantly different 
between the two treatr.i:lent modes. Concentrations in serum are plotted versus time in 
Figure 1 during continuous and Figure 2 during intermittent infusion. The mean 
concentration during continuous infusion at 12.00 h the day before sampling was 25.4 
mg/1 (sd 45) and not significantly different from the values of the day of sampling. 
Pharmacokinetic parameters during intermittent treatment are summarized in Table 
II, and during continuous administration in Table III. The AUC, TBC and urinary 
recovery were not significantly different between the two treatments, but there 
appears to be large variation not only between patients, but also within the same 
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Table L Patient Characteristics 
No. Sex Wt Length Age LBM rando- FEV1 (CI) 
mization 
(kg) (m) (y) (kg) (!/sec) 
1 m 70.0 1.86 38 58.9 c/i 0.98 
2 m 64.1 1.78 19 53.9 c/i 3.00 
3 m 662 1.76 37 54.7 ijc 1.95 
4 m 50.0 1.76 24 44.7 c/i 1.44 
5 f 40.0 1.66 21 34.2 c(> 0.54 
6 f 52.2 1.62 19 405 ijc 1.41 
7 f 49.0 1.63 20 39.1 ijc 1.54 
8 f 39.4 1.64 22 33.6 ijc 2.24 
9 f 63.0 1.75 23 482 ijc 1.08 
Mean 54.9 1.72 24.8 453 158 
Sd 11.4 0.08 7.4 92 0.74 
abbreviations see text 
FEV1 (11) 
(1/sec) 
0.86 
2.73 
1.94 
1.36 
0.63 
121 
159 
151 
137 
1.47 
0.61 
Table H. Pharmacokinetic parameters of ccftazidime after intermittent administration 
No. Ttf2'! AUC TBC Vd0 MRT urinary 
recovery 
(h) (mg.h/1) (mljmin) (!) (h) (%) 
1 156 231.0 169.6 22.7 2.07 75.9 
2 129 1693 215.7 235 1.75 63.9 
3 1.6S 261.2 140.4 205 223 642 
4 1.64 178.8 158.4 22.0 1.89 89.9 
5 1.37 231.0 1155 11.4 1.87 86.8 
6 153 292.2 97.0 13.1 2.16 942 
7 1.82 228.5 120.4 18.8 2.12 86.0 
8 1.71 1633 137.8 19.8 2.00 112 
9 1.19 173.1 192.6 20.8 1.69 75.9 
Mean 153 2143 149.2 192 1.98 78.7 
Sd 021 453 37.2 42 0.19 11.1 
abbreviations see text 
Table III. Pharmacokinetic parameters during continuous administration 
No. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
Mean 
Sd 
abbreviations see 
patient. 
text 
AUC, 
(mg.hf!) 
204.6 
218.8 
1823 
222.8 
230.7 
288.8 
196.9 
233.2 
2083 
220.7 
303 
TBC urinary 
recovery 
(rolf min) (%) 
190.1 83.7 
159.6 90.1 
159.0 77.8 
96.2 87.6 
975 89.2 
1585 91.6 
138.2 73.7 
92.9 805 
168.0 815 
140.0 84.0 
35.9 6.1 
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The correlation between the TBC and the LBM was positive (r=0.83) and significant 
(p=0.005) during continuous infusion, but failed to reach significance during 
intermittent infusion (r=0.65, p=0.06). The TBC (II) was positively correlated with 
the Vd8 (II) (r=0.83, p<O.Ol). The LBM was significantly correlated with the Vd8 (II) 
(r=0.70, p=0.04). The TBC and urinary recovery during intermittent infusion are 
negatively correlated (r=-0.53, p=0.046). 
The correlation between the TBC and the BMI was positive (r=0.65) and significant 
(p=0.02) during continuous infusion, but not during intermittent infusion (r=0.28, 
p=0.30). The BMI was not significantly correlated with the Vd8 (II) (r=0.33, p=022) 
In table IV, the pharrnacokinetic data of the CF patients are compared with those of 
8 healthy volunteers (Mouton et al., 1990). The TBC/kg of CF patients is significantly 
higher during both continuous infusion and intermittent infusion, but the TBC of the 
males is significantly higher during intermittent infusion only. The mean serum 
concentration during continuous infusion was significantly lower in the CF patients 
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Table IV. Pharmacokinetic parameters of CF patients compared to volunteers 
Volunteers (N=8) CF patients (N=9) CF males (N=4) 
umt mean Sd mean Sd mean sd 
TBC/kg, continuous mljmin.kg 1.88 0.30 256' 0.32 2.39' 033 
TBC/kg, intermittent ml(min.kg 158 0.10 2.68' 055 2.70' 055 
TBC/kgLBM, continuous ml/min.kg 237 039 3.09' 052 2.81 0.46 
TBCfkgLBM, intermittent mlfmin.kg 199 o= 3.26' 0.62 3.19' 0.61 
TBC, continuous ml/min 147.6 28.45 140.0 35.9 151.2 395 
TBC, intermittent mljmin 124.8 25.07 149.2 37.2 170.0' 303 
Concentrationjmg dose/kg mg(l 9.09 155 6.63' 0.88 7.16' 098 
Weight* kg 783 12.0 54.9' 11.4 62.2' 8.7 
LBM' kg 62.3 6.8 453' 9.2 53.0' 6.0 
Body Mass Index# kg(!' 235 2.7 185' 2.7 19.8' 2.2 
Recovery, continuous % 94.6 12.0 84.0' 6.1 84.8 5.4 
MRT, intermittent h 2.03 0.12 198 0.19 198 0.21 
T 1121.~o intermittent min 94.8 5.4 91.8 12.6 92.4 10.8 
Vdc,/kg, intermittent 1/kg 0.22 0.02 0.35' 0.08 036' 0.06 
Vela, intermittent 17.04 3.29 19.18 4.20 22.2' 1.28 
: during continuous infusion 
p<O.OS, CF w Volunteers 
when expressed as concentration reached per mg dose/kg given. 
The urinary recovery during continuous infusion, the LBM, the BMI and weight were 
significantly higher in the volunteers (p < .05), and the V dJkg (II) was significantly 
lower. 
DISCUSSION 
In this study, we compare the pharmacokinetics of ceftazidime during continuous and 
intermittent infusion in CF patients during a puhnonary exacerbation due to P. 
aeruginosa, and also compare these results with those obtained from healthy 
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volunteers. Generally, the pharmacokinetic parameters during continuous infusion and 
intermittent infusion are similar, and not significantly different from each other, but 
there appears to be a large variation between patients aswell as within the same 
patient. The urinary recovery during intermittent infusion was somewhat lower, but 
this is mainly due to the low values of patients 2 and 3. The T1/2B found after inter-
mittent infusion is comparable to results of earlier studies (Leeder et airy 1984; 
Blumer et al., 1985; Permin et al., 1983; Turner et al., 1984). We found no difference 
in half-life or MRT between the CF patients and the volunteers, in contrast to Leeder 
et al. (1984). 
Low serum-concentrations have been reported for a number of drugs in CF patients 
(de Groot and Smith, 1987; Prandota, 1988; Spino, 1991). The low serum concentra-
tions of ceftazidime have been explained by a larger volume of distribution and an 
increased clearance (de Groot and Smith, 1987), due to increased renal clearance. 
During continuous infusion, in contrast to intermittent infusion, lower serum concen-
trations can not be explained by a larger volume of distribution. However, we found 
the serum concentrations of ceftazidime as accomplished during continuous infusion 
relatively lower in the CF patients as compared to the volunteers. The lower values 
could be explained by the relatively larger LBM as compared to the total body weight 
in the CF patients and thus, since we dosed per kg, resulting in a lower dose per kg 
LBM. However, when the data are recalculated taking the LBM into account, the 
concentration reached per mgfkg LBM is still significantly lower in the CF group. 
Since the TBC is determined from the dose divided hy the AUC, the approximately 
identical values of the TBC during continuous infusion in the volunteers and the CF 
patients can thus be explained by a relatively lower dose in the CF patients due to 
their lower weight, and a relatively lower AUC (expressed here as the concentration 
reached in serum per mg dose/kg given), balancing out for the differences. This is 
supported by the significant difference in TBC when expressed per kg bodyweight or 
kg LBM. We found no evidence of increased renal clearance during continuous infu-
sion; in contrast, the recovery in the CF patients was significantly lower than in the 
volunteers, indicating increased non-urinary clearance in these patients. 
The TBC during intermittent infusion is negatively correlated with the recovery, also 
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indicating increased non-urinary elimination in some patients. In contrast to the 
results found during continuous infusion, was the significantly higher TBC during 
intermittent infusion in the CF male patients. The volume of distribution is also 
iocreased and thus offsets the iocreased clearance, resulting io minimal changes io 
T1/2ll. The difference io TBC values found between continuous and iotermittent 
infusion suggest that, for ceftazidime, altered volume of distribution may account at 
least partly for the discrepancy found with the volunteers during intermittent infusion. 
The higher TBC/kg, or relatively lower AUC, during continuous infusion may have 
consequences for dosing: if a dose would be determined from the plasma levels of 
volunteers, it would be too low if the dose were given per kg and should be adjusted. 
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CHAPTER9 
CIRCADIAN VARIATION IN SERUM CONCENTRATIONS OF 
CEFTAZIDIME AND MEROPENEM 
SUMMARY 
Serum concentrations were determined during continuous and intermittent infusion 
over 24 hours for meropenem in healthy volunteers and for ceftazidime in healthy 
volunteers and cystic fibrosis patients. Serum concentrations during continuous 
infusion of meropenem and ceftazidime were significantly higher in the early morning 
as compared to concentrations in the evening and the late afternoon. During intermit-
tent infusion, trough levels of ceftazidime in the healthy volunteers in the early 
morning were higher than those in the late afternoon. These results indicate a 
circadian variation of ceftazidime and meropenem serum concentrations, which may 
be due to variation of kidney function. 
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INTRODUCTION 
Time-kill studies of beta-lactam antibiotics on gram-negative rods show a bactericidal 
activity which is slow, proceeds with time and is maximal at relatively low con-
centrations (Vogelman & Craig, 1986). Administration by continuous infusion, to 
accomplish maintained serum concentrations, may therefore be more efficaceous than 
conventional intermittent treatment, as has indeed been shown in animal studies 
(Roosendaal et a!., 1989). During three studies, we investigated the pharmacokinetics 
of ceftazidime and the new carbapenem meropenem during continuous infusion as 
compared to intermittent infusion in healthy volunteers and cystic fibrosis patients. 
Although infusion pumps deliver a constant dose of antibiotic, serum levels may vary 
considerably during the day (e.g. Sharma eta!., 1979; Jonkman et al., 1988; Elting et 
a!., 1990). During the three studies, we had the opportunity to observe time-related 
differences of serum concentrations. 
MATERIALS AND METIIODS 
In two studies, the pharmacokinetics of ceftazidime and meropenem were studied 
during continuous and intermittent infusion in eight healthy volunteers in a cross-over 
fashion. Details have been published elsewhere (Mouton et a!., 1990; Mouton & 
Miche~ 1991). Briefly, the start of the ceftazidime infusions was at 430 p.m. (75 
mgjkg total dose, given as 25 mgjkg q8h or 60 mg over 24 hours with 15 mg/kg as a 
loading dose), and the start of the meropenem infusions at 7 30 p.m. (30 mgjkg total 
dose, given as 10 mg/kg q6h or 30 mgjkg over 18 hours). During a third study, the 
pharmacokinetics of ceftazidime was studied in Cystic Fibrosis patients during a 
pulmonary exacerbation due to P. aeruginosa. After at least two days of therapy (100 
mgjkg total daily dose, given as 333 mgjkg q8h or 100 mg/kg over 24 h), serum 
samples were taken. Intermittent infusions were given at 8 a.m., 4 p.m. and 12 p.m. 
Serum samples were taken at appropiate time-points, and analyzed by HPLC. The 
Wilcoxon matched pairs test was used to determine differences between serum levels 
(Blalock, 1981). 
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Figure I. Mean serum concenirations of ceftazidime over 24 hours (60 mg/kg/24 h 
and 15 mg/kg as a loading dose) in 8 volunteers. The 8.30 a.m concentrations are 
significantly higher than those at 0.30 a.m and 4.30 p.m. 
RESULTS 
In Table I, the mean values of ceftazidime and meropenem serum levels are shown 
during continuous and intermittent adntinistration at night, in the early morning and 
in the late afternoon. For ceftazidime given to healthy volunteers, the concentrations 
during continuous infusion were significantly higher in the early morning compared to 
the late afternoon and at night. Figure 1 shows the rise and fall of the ceftazidime 
serum levels over 24 hours, with the highest concentration at 830 a.m.. During 
intermittent infusion, the trough levels in the early morning were significantly higher 
than those at 4.30 p.m.. The serum concentrations of meropenem during continuous 
infusion were significantly higher in the early morning as compared to the late after-
noon and at night. During intermittent infusion, there was no significant difference. In 
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Table L Influence of the time of the day on serum concentrations (sd) of ceftazidim.e and meropenem 
Healthy volunteers, ceftazidime (n=8) 
Continuous, 25 mgjkgfh 
Intermittent, 25 mg/kg q8h 
mean ceftazidime level (sd) (mg/1) 
0.30 am 
22.8 (3.6)" 
nd 
830am 
263 (6.6) 
7.1 (12) 
Healthy volunteers, meropenem (n=8) 
Continuous, 1.66 mg/kg/h 
Intermittent, 10 mg q6h 
Cystic Fibrosis patients 
Continuous, 4.16 mg/kgfh (n=13) 
lntennittent, 333 mg/kg q8h (n=9) 
mean meropenem level (sd) (mg/1) 
1130 pm 
5.7 (0.4)" 
nd 
730am 
6.8 (0.8) 
0.7 (0.2) 
mean ccftazidime level (sd) (mgjl) 
8.00 am 
29.4 (3.8) 
4.1 (1.5) 
430pm 
19.6 (1.8)" 
4.0 (0.7)"' 
130pm 
6.0 (0.6)"' 
0.6 (0.2) 
4.00 pm 
263 (4.9)"' 
33 (1.2)" 
@ P < 0.05 and · P < 0.1 as compared to early morning sample (Wilcoxon matched pairs test) 
the cystic fibrosis patients, ceftazidime concentrations in serum in the early morning 
were significantly higher as compared to the afternoon during continuous infusion, 
during intermittent infusion the difference did not reach significance. 
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DISCUSSION 
Rhythmic changes in phannacokinetic parameters in men dependent upon dosing 
time have been reported for many drugs (Reinberg, Levi & Smolenski, 1984; 
Brugueroll, 1987), but only for a few antibiotics (Dettle & Spring, 1966; Kabasakalian 
et a!., 1970; Di Santo, Chodos & Halberg, 1975; Sharma et al., 1979; Jonkman et al., 
1988; Elting et al., 1990). Differences in serum levels may be related to variation in 
absorption, metabolism or excretion (Reinberg et al., 1984; Reinberg, Smolenski & 
Labrecque, 1985). Ceftazidime and meropenem were both given intravenously, so 
differences in absorption do not have to be considered. Ceftazidime is almost comple-
tely excreted by the kidneys (Mouton et al., 1990; Welage, Schultz & Schentag, 1984). 
Kidney function, as measured by urine volume and glomerular filtration rate, is 
known to increase during the day and decrease during the night, and be independent 
of fluid intake (Wesson & Lauler, 1961), and thus offers the most likely explanation 
for the differences of ceftazidime serum levels. A similar explanation was given by 
Elting et al. (1990), who found circadian variations in serum amikacin levels. 
However, the authors discuss two possible confounding factors in their study. The first 
was differences in specimen handling, which in our studies was similar for all samples. 
Their second confounding factor was possible interference with other antibiotics, since 
the concentrations were measured during combination therapy, while during our 
studies monotherapy was given. Meropenem is excreted via the kidneys for 60-70% as 
the unchanged compound (Harrison et al., 1989; Mouton & Michel, 1991), and 
although kidney function probably may explain the results, it can not be excluded that 
metabolization also varies during the day (Reinberg et al., 1984). 
Our findings suggest that there are variations in serum levels of ceftazidime and 
meropenem, and that these are higher in the early morning as compared to late 
evening and late afternoon concentrations. Although these differences are probably 
not clinically relevant for these compounds, the time of the day should be considered 
when interpreting serum concentrations. 
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CHAPTER 10 
PHARMACOKINETICS AND KILLING OF BACTEIRIA IN VITR.O 
10.1 
GENERAL INTR.ODUCTION AND REVIEW 
To determine the susceptibility of a micro-organism, usually a Minimal Inhibitory 
Concentration (MIC) is determined. This method has two distinct disadvantages: (1) 
the endpoint is growth or no-growth after a fixed point of time without taking the 
growth or killing kinetics into account and (2) the medium in which the micro-
organism grows contains a steady state concentration of antibiotic, while in the body 
there is a fluctuation of antibiotic concentrations as a result of intermittent dosing 
and clearance of the antibiotic. 
To overcome the fust problem, killing-curves are sometimes used, and it has been 
shown in several studies that the killing of the bacteria by various classes of an-
tibiotics does indeed differ. The classical paper of Vogelman and Craig (1986) descri-
bes the effect of ticarcillin and tobramycin on Pseudomonas aeruginosa. Killing of 
bacteria by ticarcillin was slow, continued in time, and high concentrations contri-
buted no extra effect. In contrast, tobramycin exerted a fast killing, which was concen-
tration dependent. The results of a similar study on ceftazidime and tobramycin are 
shown in Figure la and lb respectively. For ceftazidime, the killing curves at concen-
trations much higher than the MIC do not essentially differ from each other. Killing 
starts almost immediately and continues in time, as can been seen from the steady 
decrease in surviving bacteria. For tobramycin concentration dependent killing is 
evident, and at the highest concentration used killing is almost immediate. Killing 
curves thus provide information on the pharmacodynamics of an antibiotic, which an 
MIC does not. 
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Figure la and lb. Killing cwves of ceftazidime (above, Figure la) and tobramycin 
(below, Figure lb). Inocula of 5 x 10"' cfu/ml P. aeruginosa were incubated with 
ceftazidime or tobramycinfor 24 hours in a range from .25 x MIC to 16 x MIC 
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Figure 2 Principle of models based on dilution. The culture is diluted with fresh 
broth to obtain a concentration gradient of the antibiotic. Left: simple dilution. 
Right: diluted culture is eliminated to retain an equal volume (V). 
The second problem, concerning fluctuation of antimcrobial concentrations, was 
recognized many years ago, and several models have been evolved to simulate plasma 
concentrations in humans. In 1968, Sanfilippo and Morvillo developed an in vitro 
kinetic model, that minticked plasma concentrations as observed in vivo. The 
apparatns consisted of a series of flasks containing a bacterial culture to which an 
antibiotic was added. Using a peristaltic pump to control the flowrate, sterile diluent 
broth was added to simulate decreasing concentrations of antibiotic. In this way, it 
was possible to smdy the effect of decreasing concentrations on the killing of bacteria 
(Figure 2). Two disadvantages were recognized in this system. One was an increase in 
culture broth during dilution and the amount of broth needed to dilute the culture, 
which increased exponentially In time. The second drawback was the pump flow rate 
which, with increase in time, yielded concentrations which did not decrease exactly 
exponentially. This was solved in subsequent studies by keeping the culmre volume 
constant, for instance by keeping the flow out of the culmre flask the same as the 
diluent flow (Otaya, Ozawa and Goto, 1976; Bergan et al., 1980). Although most of 
the problems encountered with the diluent method were resolved technically by 
Table I. In vitro pharmacokinetic models based on dilution. 
tmtlwrs 
O'Grady & Pennington, 1966 
Sanfilippo & Morvillo, 1968 
Otoya et al., 1976 
Grasso et al., 1978 
Nishida, 1978 
Greenwood & Grady, 1978 
Leitner et al., 1979 
Bergan et al., 1980 
Murakawa et al., 1980 
Shah, 1980 
Klaus et aJ., 1981 
Greenwood & Tupper, 1982 
Gerber et al., 1982 
nwdel description 
dilution, model to study cystitis 
reproduction plasma levels, series of flasks, 
flow control not very reliable, much diluent 
needed 
pressure pump to keep central compartment 
at the same volume 
regimens used 
dilution effect on growth of bacteria 
sulfonamides on S. aureus 
cefalothin, erythromycin and kanamycin div. spp. 
pressure pump, mono and biexponential con· cefazolin against E. coli and Klebsiella sp. one dose. 
centration·time curves, continuous monitoring 
stepwise dilution cefazolin, ccfaloridine and cefalothin against E. coli 
full automated system of a simulation of the 
bladder 
stepwise dilution 
two pressure pumps, continuous monitoring 
two-compartment open model, continuous 
decline concentration 
ftlter to prevent removal of bacteria 
model of Grasso et al., 1978 
two chambers, one with bacteria, one with a 
changing antibiotic concentration, diffusion 
through membrane 
model of Grasso et al., 1978 
cephalosporins against div spp. 
cefazolin, cefamandole, cefuroxime, cefoxitin, one dose. PAE? 
amoxicillin on E. coli, beta-lactamase production 
gentamicin, 2 doses vv continuous infusion. no difference. P AE. 
.... 
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Table I, continued 
t1llJ}um 
Schneider et al., 1982 
Bauernfeind, 1982 
Haller, 1982 
Van Etta et a!., 1982 
Shah, 1983 
Tosch and Schnell, 1984 
Wiedemann & Secberg, 1984 
Seeberg & Wiedemann, 1985 
White et aJ., 1985 
Sous & Hirsch, 1985 
Haag et al., 1986 
White et al., 1989 
Bauernfeind, 1992 
moth/ tfescripli011 
filter 
stepwise dilution 
stepwise dilution 
model of Murakawa et al., 1980 
model of Shah, 1980 
dilution and filter 
model of Grasso et al., 1978 
model of Grasso, et al., 1978 
model of Grasso et al., 1978 and Murakawa et 
at., 1980 
model of Grasso et al., 1978 
model of Grasso et al., 19"78 
model of Grasso et al., 1978 
stepwise dilution 
regimens used 
cefroxadine, cefalex:ine, cefradine on Gram-negatives 
ceftriaxone and netilmicin on P. aeruginosa. synergism. 
azlocillin and sisomycin on P. aeruginosa 
cefapirin, one dose. effect of ratio of surface area to volume on the 
penetration of antibiotics in extravascular spaces. 
cephalosporins and netilmidn on Gram-negatives 
comparison of dilution models and models with filter. results were 
overlapping 
cefotiam, one dose. influence of beta-lactamases on killing kinetics. 
correlation between killing ability and MIC only for MIC > 16 mg/1. 
ampicillin, amoxycillin, cephalosporins. 3 doses. development of 
resistance. 
amoxicillin, ticarcilli.n and clavulanic acid against P. aeruginosa. 
gentamicin enhances effect 
phcnoxymethylpenidllin against S. aureus. one dose. 
artifacts in dilution pharmacokinctic models 
ampicillin against E. coli 
teicoplanin, mezlodllin, netilmicin and ciprofioxacin alone and in 
dual combinations against E. faecalis 9 
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Table II. In vitro pharmacokinetic models based on diffusion or dialysis. 
au1lwr:o 
Al-Asadi et al., 1979 
Drugeon ct al, 1979 
Zinner et al., 1981 
Toothaker et al, 1982 
Blaser et al, 1985 
Blaser et al., 1985 
Zinner et al., 1985 
Reeves, 1985 
Guggenbichler et al., 1985 
Blaser et al., 1985 
Blaser et al., 1985 
Shah, 1985 
Bergan and Carlsen, 1985 
Zinner & Blaser, 1986 
model description regimens used 
two tubes separated by membrane, one of the gentamicin against E. coli 
chambers with declining antibiotic concentrati-
on. blocking of pores by bacteria. 
dialysis unit aminoglycosides against div. spp. 
artificial capillary unit with polysulphone fi- azlocillin against P. aeruginosa 
hers 
hemodialysis unit 
two compartment model, multiple artificial 
capillary units 
two compartment model, multiple artificial 
capillary units 
two compartment model, multiple artificial 
capillary units, antibiotic combinations 
hollow fiber dialyser 
dialyser 
dialysis 
dialysis 
membrane ftlter 
membrane filter 
dialysis 
ampicillin against E. coli 
piperacillin with thienamycin or amikacin, azlocillin with netilmicin 
against P. aeruginosa 
ciprofloxacin against S. marcescens. four doses. 
various antimicrobials against div. spp. 
netilmicin intermittent and continuous on P. aeruginosa. intermittent 
favorable 
ceftazidime-netilmicin combinations on P. aeruginosa. synergism. 
imipeneru against Gram-negative rods in blood 
various antimicrobials against div. spp. 
discrepancy synergism in vitro pharmacokinetics and other methods 
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Table II, continued 
authors 
Navashin et al., 1989 
Firsov et al., 1990 
Silley et al., 1990 
Vergeres and Blaser, 1991 
nwdel tkscriplion 
membrane niter 
membrane filter 
membrane filter 
membrane filter 
regimens used 
sisomycin on E. coli 
sisomycin on P. aeruginosa, E.coli and K. pneumoniae 
cefuroxime axetil kill kinetics 
various antimicrobials against P. aeruginosa and S. epidermidis in 
biofilm 
~ l 
.... 
<:::> 
.... 
th 
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Figure 3. Principle of models based on diffusion The broth with antibiotic in the 
central compartment is diluted with fresh broth from the dilution reservoir (1), while 
at the same time the same amount is eliminated (2). The volume thus remains 
constant and a log-linear concentration gradient is obtained. The contents in the 
central compartment are pumped through diffusive capillaries or along a membrane 
(3), communicating freery with the bacterial culture through the membrane (4), thus 
creating a concentration gradient in this compartment as welL The size of the pores 
of the capillaries allow onry small molecules to pass through. It is possible to place 
several peripheral compartments in series, and thus to study several cultures 
simultaneousry. 
various authors (Table I), the major disavantage still remained dilution of not only 
the antibiotic, but also of the bacterial culture (Figure 2). To overcome this problem, 
Shah (1980) inserted a nticro-glass filter before the outflow to prevent removal of 
bacteria. 
The models described so far were all based on dilution of the original culture. In 
1979 Al-Asadi, Greenwood and O'Grady, as well as later authors, described a model 
based on diffusion (Table 2). Two tubes were separated by a membrane, one tube 
contained the antibiotic solution, the other the culture. By diluting the antibiotic 
solution a gradient was obtained, and as the broth with antibiotic was free to cross 
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the membrane, a gradient was obtained in the culture as well. One of the drawbacks 
of the model however, was that the bacteria blocked the membrane pores, thereby 
impeding diffusion. This problem was solved in several ways. Drugeon, Maurisset and 
Courtieu (1979), described a model based on a dialysis unit, which appeared to be 
very efficient. In 1981 Zinner, Husson and Klasterj.,:y described a device based on an 
artificial capillary unit, which was later perfected by Blaser (1985) and Blaser, Stone 
and Zinner (1985a,b; Figure 3). The model ultimately consisted of serially placed 
bacterial compartments interfacing with a central compartment through artificial 
capillaries. The antibiotic gradient obtained in the central compartment through 
dilution, was reflected in the peripheral compartment. The model also allowed simul-
taneous elimination kinetics of two drugs with different half-lives, to study antibacte-
rial effects of drug combinations. 
The model which was chosen for the studies described below is a modification of the 
model as described by Blaser (1985). 
purpose of the study 
Although there are several studies describing the efficacy of beta-lactams during 
decreasing concentrations in vitro, there are no studies which compare the effect of a 
continuous versus an intermittent dosing regimen over several dosing intervals. To 
allow us to study the killing kinetics of ceftazidime on P. aeruginosa during continuous 
and intermittent infusion, we developed an in vitro pharmacokinetic model, and 
applied these dosing regimens on P. aeruginosa. Several strains with different MICs 
were used to determine the interaction between susceptibility and dosing regimen. 
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10.2 
KilLING OF PSEUDOMONAS AERUGINOSA DURING CONTINUOUS AND 
INTERMITI'ENT INFUSION OF CEFrAZIDIME IN AN IN VI1RO 
PHARMACOKINETIC MODEL 
SUMMARY 
An in vitro pharmacokinetic model mimicking human serum concentrations was used 
to study the efficacy of continuous infusion and intermittent administration of 
ceftazidime over a period of 36 hours. The model consisted of a central compartment 
interfacing with dialyser units containing the bacterial cultures. The daily dose was 
300 mg/1/24 hours given either as a continuous infusion or as three bolus doses. The 
concentrations of ceftazidime were determined by HPLC, and efficacy was deter-
mined by bacterial couots. The dosing regimens yielded top and trough concentrations 
after the fourth dose of 92.3 .±. 8.0 and 1.4 .±. 0.9 mg/1, respectively. Continuous 
administration yielded concentrations of 20 mg/L To study efficacy, three P. 
aeruginosa strains, ATCC 27853, CF224 and CF224M were used. The MIC for cefta-
zidime of these strains was 1, 4 and 16 mg/1, respectively. Strain CF224M was killed 
initially during both regimens, and then started to regrow. At the end of the fourth 
dosing interval, i.e. after 32 hours, there was no difference between the regimens. 
Regrowth was due to the emergence of resistant strains as demonstrated by a higher 
MIC and the presence of beta-lactamase in the medinm. The strains ATCC 27853 
and CF224 were killed initially during both dosing schedules, and after the first 
dosing interval viable counts were sintilar. However, after the fourth interval, there 
was a marked difference between bacterial counts during continuous and intermittent 
infusion, being 22 and 3.8 1"log respectively, demonstrating a higher efficacy during 
continuous infusion. 
The results indicate that, in the absence of other factors, a sustained level of cef-
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tazidime around or slightly above the MIC is not high enough to maintain efficacy 
over more than one (8 h) dosing interval, and probably should be around 4 to 5 times 
the MIC. When sustained concentrations higher than 4 times the MIC are employed, 
continuous administration in this model is more efficacious than intermittent dosing. 
INTRODUCTION 
Time-kill curves of beta-lactam antibiotics on P. aeruginosa show time dependent 
killing which is maximal at relatively low concentrations (Vogelman and Craig, 1986). 
Concentrations much higher than the MIC contribute no extra effect. From these 
experiments, it can be deduced that continuous serum concentrations above the MIC 
of the ann'biotic used to combat the micro-organism in question, should be more 
efficacious than declining concentrations as observed after intermittent dosing (Cars 
and Craig, 1991; Craig and Ebert, 1992). During the latter regimen, concentrations 
fall below the MIC during part of the dosing interval. It has been shown in several 
animal models that continuous infusion is indeed more efficacious than intermittent 
dosing (Gerber et al., 1983; Mordenti et al., 1985; Roosendaal et al., 1989). However, 
the half-life of most drugs is severely shortened in the animals studied and con-
clusions regarding the pharmacodynamics in humans are difficult to make (Gerber et 
al., 1991). For, if the shortened half-life is taken into account, the time below MIC 
applies for almost the entire dosing interval, which is contrary to the situation as 
observed in humans. This has, however, partly been overcome by fractional dosing to 
mimick human pharmacokinetics (Gerber et al., 1986). 
In vitro simulation of human pharmacokinetics may thus give additional information 
with respect to killing kinetics of micro-organisms. Several in vitro pharmacokinetic 
models have been described to simulate human pharmacokinetics, based on either 
dilution or diffusion (see 10.1). We developed an in vitro pharmacodynamic model 
based on a dialyser unit, which is described here. This model was subsequently used 
to study the efficacy of continuous versus intermittent infusion of ceftazidime against 
P. aeruginosa over a period of 36 hours. Although there are some reports suggesting a 
better efficacy in vitro when dosing beta-lactam antibiotics continuously (Gerber et 
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al., 1982), in these studies they were given in combination with an antinoglycoside. In 
other reports the MIC is compared with the results obtained in the pharmaco-
dynamic model (Klaus et al., 1981; Seeberg and Wiedemann, 1985; White et al., 
1989), but circumstances during which an MIC is determined differ from those in the 
model. Furthermore, all these studies were based on dilution models, and although 
correction for dilution of the bacteria (White et aL, 1987) can be made, artifacts due 
to dilution have to be precluded (Haag et al., 1986). 
In the present study, we used a standard dose yielding concentrations comparable to 
those observed in humans during treatment. Three P. aeruginosa strains with different 
MICs were examined. 
············· 
,---i:: ... ::::::::::···········:::i<'--. 
Figure 4. Schematic diagram of the two-compartment modeL Antibiotic is added to 
the central compartment by bolus injection or by use of a pump. The volume of the 
central compartment is kept constant by setting the pumps from the dilution 
reservoir and to the waste reservoir at the same rate, yielding an exponential decline 
of the concentration of the antibiotic. The central and the peripheral compartment 
communicate through the artificial capillaries. Two peripheral compartments are 
shown here; in experiments up to four were placed in series. 
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METIIODS 
Model. A two-compartment model consisting of one central compartment and several 
peripheral companments was designed to expose bacteria to changing antibiotic 
concentrations mimicking human pharmacokinetics. Figure 4 shows a schematic dia-
gram of the model. Antibiotic was added to a central compartment containing broth. 
This central compartment was diluted from a diluent reservoir using a peristaltic 
pump (Biorad econo pump, Veenendaal, NL). Antibiotic containing broth was pump-
ed from the central compartment to the elimination reservoir at the same pump rate, 
thus keeping the central compartment at a constant volume. The peripheral compart-
ments consisted of disposable dialyser units (ST23, Baxter, Utrecht, NL) with a pore 
diameter of 2.8 nm. Up to four serially placed dialysers were used to allow simul-
taneous cultures to be studied. A peristaltic pump (Biorad econo pump, 175 ml/min) 
was used to circulate the culture in each unit. Inoculation and sampling was done 
through silicone injection points (BSM-VOl S, Hospal, Uden, NL) with sterile need-
les. Each peripheral unit contained 150 m1 bacterial culture. The central compartment 
was pumped through the artificial capillaries of the dialyser unit by a peristaltic pump 
(Rhone Poulenc Medical 440, 125 ml/min). The central and peripheral compartments 
were placed on a shaking apparatus (125 rpm) to provide optimum dilution of the 
injected antibiotic and to accelerate bacterial growth in the peripheral compartments. 
Air was blown into the broth of the central compartment through an air filter. The 
complete system was placed in a room at 37°C ambient temperature. 
Media. Mueller-Hinton Broth (Difco, A' darn, NL) supplemented with Ca2+ (22 mg/1) 
and Mg2+ (12 mg/1) was used in all experiments (MHBJ. 
Strains. P. aeruginosa ATl (ATCC 27853), P. aeruginosa CF4 (CF224) and P. 
aeruginosa CF16 (CF224M) were used. Strain CF4 was originally isolated from a 
cystic fibrosis patient. CF16 is a laboratory mutant of strain CF4. The MlCs for 
ceftazidime were 1, 4 and 16 mg/1 for P. aeruginosa ATl, CF4 and CF16 respectively. 
Both CF strains showed the same growth characteristics as strain AT1 (see below). 
Antibiotic. Ceftazidime was obtained from Glaxo (Zeist, NL). Stock solutions were 
prepared according to the guidelines of the National Committee for Clinical Labora-
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tory Standards (NCCLS, 1990). 
MIC and growth curves. Minimal Inhibiting Concentrations (MIC) were determined 
by both a standard agar dilution method and a microdilution method (NCCLS, 1990). 
Growth curves were made as follows: one colony from a fresh overnight culture on 
ISO-sensitest agar (Oxoid CM 471) was suspended in MHB, and incubated overnight 
on a shaking apparatus (200 rpm) at 37"C. The inoculum was obtained by diluting this 
culture to approximately 5*1o' cfu/ml and incubation at 37"C while shaking. Samples 
of this log-culture were taken at t = 0, 1, 2, 4, 6 and 24 h and diluted serially tenfold 
in cold sterile saline on ice. 100 1'1 of each dilution was plated on ISO-sensitest agar 
and incubated overnight at 37°C. Growth curves were also determined in the model 
described above, only without injection of antibiotic. At t=O eacb of the the periph-
eral compartments were filled with a Jog-culture of approximately 5* 1o' cfu/rnl. 
Samples were taken at t = 0, 1, 2, 4, 6, 24h for cfujml counts as described above. 
Pharmacokinetic and killing curves. The in vitro activity of changing ceftazidime 
concentrations against three strains was tested in the model described above. For the 
intermittent infusion experiment at t=O (immediately after the inoculation of the log-
cultures into the peripheral compartments) ceftazidime solution (100 mgjl/dose) was 
injected in the central compartment. This was repeated after each 8th hour, con-
tinuing for 36 h. Samples were taken at t = 0, before and 10' and 30' after each dose 
and further at every hour until t=10 h, then every two hours until t=16 h, and at 
t=25 h, 28 h, 33 h and 36 h. For the continuous infusion experiment at t=O an infu-
ser (Braun, NL) was used providing the same daily dose of ceftazidime as during in-
termittent infusion (300 mg/l/24h). Every 12 h the ceftazidime solution in the infusor 
was replaced. Samples were taken at t = 0, 10', 30', 1 h every hour until t= 10 h and 
then every 2 h until t=14 h, t=24, 26, 28, 30, 32 and 36 h. The samples used for 
viable counts were immediately washed (3*) with sterile saline on ice before the 
tenfold dilutions were made. Samples taken for ceftazidime assay were stored at -
70°C. Samples were assayed for ceftazidime by high performance liquid chromato-
graphy (HPLC) as described earlier (Mouton et al., 1990). 
Other assays. Beta-lactamase production was determined qualitatively in the original 
samples from t=O, 8, 14, 24, 32 and 36 h with a standard iodometric method (Neu, 
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1980). Briefly, 100 1'1 sample was added to 100 1'1 freshly prepared penicillin G 
solution (6000 mg/1). Two drops of starch solution (1%) were added and incubated at 
room temperature for 30-60'. After addition of iodine reagent, disappearance of tbe 
!ben blue colored mix was considered positive. 
The MICs of tbe isolated strains at these time points and pH of tbe medium were 
also determined. 
Analysis. The growtb rate I' was determined during log-fase (Carlberg, 1986). 
Pharmacokinetic analysis of tbe time-concentration curves was done using tbe 
equations of Allen et al. (1982). Pharmacokinetic parameters were estimated using tbe 
SAS NUN computer program package (SAS, 1990) using a one-compartment open 
model. The Area Under the time-Concentration Curve (AUC) was determined over 
tbe first 32 h using tbe log-linear trapezoidal rule. 
RESULTS 
Phannacokinetic curves. A typical example of the pharmacokinetic curves obtained 
during intermittent and continuous infusion are shown in Figure 5. The curves were 
reproducible, and the pharmacokinetic parameters in each of the dialyser units were 
comparable (Table III). The top and trough concentrations during intermittent infu-
sion as well as the half-lives did not differ significantly over the five doses (Table Ill). 
The AUC from 0 to 32 h was slightly higher during intermittent infusion (678.8 .±. 
117.8 mg.h/1) compared to continuous infusion (609.5 .±. 13.4 mg.h/1). The mean con-
centration of ceftazidime was 19.8 .±. 1.6 mg/1 at tbe end of the fourth dosing interval 
(Table III). 
Growth curves. The growtb rates I' ( .±. sd, means of four curves) of the strains AT1, 
CF4 and CF16 were 1.07 .±. 0.27, 0.83 .±. 0.28 and 1.01 .±. 0.22 1/h respectively and 
not statistically significantly different from each other. The growth rates in tbe model 
were 1.18 .±. 0.24, 1.03 .±. 0.18 and 1.02 + 0.24 1/h respectively. 
Killing curves. Killing curves of tbe P. aeruginosa strains exposed to ceftazidime are 
shown in Figure 6. During intermittent infusion, bacteria were killed initially but 
started to regrow after 7h. After each dose, there was some killing or suspension of 
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Table HL Pharmacokinetic parameters during intermittent and continuous infusion for each of the five 
doses. All values are means .±. sd of seven curves. 
dose 
parameter 1 2 3 4 5 
trough (mg/1) 0 0.62.±_0.16 2.2.±_1.6 1.4.±.09 2.2.±_0.8 
peak (mgjl) %3;t_7.8 1023.±_14.8 845.±_9.8 923.±_8.0 86.9;t_7.1 
T,,, (h) 150;t_0.23 1.49±_0.23 1.67.±_032 156.±_0.17 
mean concentration at 21.1.±_2.0 19.8.±.1.1 19.7.±.23 19.8.±_1.6 21.2.±.1.9 
end interval 
(continuous, mgjl) 
growth, but then growth was resumed; this was most apparent for strain CF16. During 
continuous infusion, strains ATl and CF4, with an MIC of 1 and 4 mg/1, respectively, 
were killed initially and then started to regrow for a few of hours, where upon the 
number of bacteria/ml remained constant during remainder of the experiment. After 
the first dosing interval of 8 h there was no difference between killing by continuous 
and intermittent infusion for strains ATl and CF4. In contrast, after each subsequent 
dosing interval, there was an increasing difference between efficacy of intermittent 
and continuous infusion in favour of the latter, which was most marked after the last 
dosing interval, i.e. after 32h (Table IV). The difference was somewhat lower for 
strain ATl than for strain CF4 due to the emergence of a resistant mutant in one 
experiment whereby the MIC of ceftazidime increased to 64 mg/1 (see below). Strain 
CF16 was killed initially, but during continuous infusion numbers of bacteria were not 
reduced to the same extent as during intermittent infusion. Regrowth started at ap-
proximately the same time during both regimens and after 32 h the numbers of CFU 
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were equal (Table IV). 
Emergence of resistent strains. To determine whether resistent strains emerged in the 
course of time, the MICs of strains isolated during the experiments were determined. 
The MIC of the ATl strain remained constant, except for one experiment dnring 
continuous infusion. The MIC of the strains isolated during the experiments with CF4 
and CF16 increased during both continuous and intermittent infusion, and amounted 
to 128 mg/1 after 24 hours. Thereafter no strains with higher MIC's could be isolated. 
Determination of beta-lactamase in the medium of the CF16 strain revealed that a 
detectable amount of beta-lactamase was present at the same time as isolation of the 
resistant strains, but not before. Beta-lactamase could also be detected after the 
emergence of the resistant ATl strain during continuous infusion. In contrast, beta· 
lactamase could not be detected in the samples of the experiments with strain CF4, 
either during continuous or intermittent infusion. 
pH measurements of the samples showed no deviating values. 
Table IV. Changes in bacteria concentrations between 0 and 8 hours (after 1 dosing interval) and 0 and 
32 hours (after 4 dosing intervals) of treatment with intermittent and continuous dosing 
regimens of ceftazidime. 
Change in bacterial concentration" 
Strain Interval 
(MIC mg(l) (h) Intermittent Continuous Difference 
ATCC27853 8 3.3 3.7 0.4 
(1) 32 0.7 2.9 2.2 
CF4 8 3.3 3.6 0.3 
(4) 32 0.9 4.7 3.8 
CF16 8 2.8 1.3 ·1.5 
(16) 32 -2.9 ·3.2 ..0.3 
"' Given as change in 1ilJ.og CFU/ml between t=O hand t=32 h (geometric mean of at least 2 experiments) 
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DISCUSSION 
Several models have been used to mimic plasmaconcentrations (see 10.1). The model 
developed here, based on diffusion, enables to study killing kinetics during continuous 
and intermittent dosing regimens. The model proved to adequately reproduce phar-
macokinetic profiles. 
In the present study, the model was used to determine whether continuous admini-
stration of ceftazidime is more efficacious than intermittent dosing using dosing 
regimens yielding concentrations comparable to those observed in vivo. The half-life 
chosen for these experiments was approximately 15 h. This is in accordance with 
values found in vivo (Tjandramagra et al, 1982; De Klerk et al, 1983; Mouton et al., 
1990). The daily dose chosen yielded concentrations comparable to those found in 
vivo. The killing curves of P. aeruginosa show that, during the time-course of the 
experiment, continuous infusion was more efficacious than intermittent infusion for 
the strains ATl and CF4. Although a bolus dose exerted killing initially, the P. 
aeruginosa strains started to regrow after several hours. At each new dose growth was 
halted for some time, or some killing was achieved, but then the bacteria resumed 
growing. A similar observation was made for amoxicillin (Klaus et al., 1981; Seeberg 
and Wiedeman, 1985) and ampicillin (Toothaker et al., 1982; White et al., 1989) on E. 
coli. After the start of continuous infusion bacteria were killed as well, but regrowth 
was substantially Jess cir hardly present during continuous infusion compared to inter-
mittent infusion. This is in agreement with the hypothesis and some observations that 
Gram-negatives exposed to beta-lactams resume growth when concentrations fall be-
low a certain level (Craig and Ebert, 1991) and that high concentrations do not exert 
an additional effect as for instance for the quinolones (Blaser et al., 1987). 
The most consistent index of bactericidal activity found by White et a/_ (1989), when 
studying efficacy of ampicillin on E. coli, was the AUC and not the time above the 
MlC (T Mic)- The T MIC did not covary strongly with the MlC, and the authors suggest 
that the high frequency of emergence of resistant strains may have masked the 
importance of the T Mic- Since during continuous infusion the T MIC was incessant when 
related to the strains AT1 and CF4 at the start of the experiments, and continuous 
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infusion was more efficacious than intermittent infusion, we conclude that the T MIC is 
an important parameter. The suggestion of White et a/. (1989) that their failure to 
find T Mic to be an imponant parameter may have been caused by the high frequency 
of emergence of resistant strains may, therefore, be correct. Smdying efficacy of beta-
lactarns in patients with pnenmonia, Schentag (1991) also found the TMic to be 
important. 
It has been argued that the the emergence of resistance, or the continued isolation of 
strains is possibly an anifact of in vitro systems due to the adherence of bacteria to 
the walls of the incubation flasks (Haag et a/., 1986). This observation was made in 
dilution models, and control experiments in these type of models can rule this out 
(Haag et a/., 1986; White et a/., 1989). In the diffusion model used in the present 
smdy, the importance of adherence of bacteria is not easily assessable. However, if 
adherence were a main determinant of the outcome of the smdies, one ntight expect 
that there would have been no difference in the outcome of the dosage regimens. 
To determine whether the MIC itself may be of influence on the interaction between 
bacteria and antibiotic, we exantined three strains. The P. aeruginosa strains CF4 and 
CF16 chosen were fourfold and sixteenfold less susceptible for ceftazidime, respec-
tively, than strain ATl, and the growth rates were comparable with each other. 
Although the concentration during continuous infusion was maintained at approxi-
mately 20 mg/l ceftazidime, which is higher than the MIC of strain CF16, this 
particular strain starred to regrow after some time. This was due to the appearance of 
strains with MICs up to 128 mg/1, a phenomenon that was also observed during 
intermittent infusion. Regrowth due to resistant subpopulations has also been 
observed in other smdies with a comparable model. However, in these smdies the 
bacteria were exposed to enoxacin and gentanticin, which belong to another group 
(Blaser et a/., 1987; Zinner and Blaser, 1985). Beta-lactamase, not detectable in the 
earlier samples, was present in the medium from approximately the same time on-
wards, possibly facilitating regrowth. It also indicates that the apparent resistance was 
probably due to the production of beta-lactamase by P. aeruginosa. The regrowth 
during continuous adntinistration, despite continuous concentrations above the MIC, 
imply that these concentrations are not high enough to prevent regrowth. 
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In contrast to this observation for strain CF16 was the appearance of resistant strains 
of CF4 with a high MIC during both continuous as well as during intermittent 
infusion. These strains were highly resistant as determined by their MIC, yet ap-
preciable growth did not occur. The absence of growth of the isolated mutants of CF4 
is not easy to explain. It could be that, if the experiment had lasted longer, regrowth 
would have been observed, although this did not occur during the 12 hours that the 
strain was present. Presence of beta-lactamase could not be detected, suggesting that 
resistance was cell wall mediated in these cases. 
The results of these experiments suggest that, when the antibiotic is the only agent 
present to exert efficacy, as is the case in neutropenic patients, a sustained level 
around or slightly above the MIC is not high enough. The strains exposed to a 
sustained concentration of 5 times the MIC or more were inhibited in their growth, 
indicating that a concentration 4 to 5 times the MIC are effective. When sustained 
concentrations higher than 5 times the MIC are employed, continuous administration 
in this model is more efficacious than intermittent dosing. 
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SUMMARY 
Pulmonary infections are still the major cause of morbidity and mortality in patients with 
cystic fibrosis ( CF). Although the possibilities of treatment have greatly increased over 
the years, the decline in lung function, as a result of destruction of lung tissue by 
infections, ultimately leads to death at a relatively early age. The purpose of the studies 
presented in this thesis was threefold. In the first part (Chapters 2-5), the problems which 
emerge during antibacterial treatment in CF patients are discussed. The second part 
(Chapters 6-9) presents the results of several studies which were all based on the 
assumption that continuous infusion of beta-lactam antibiotics may lead to better 
treatment results compared to the usual intermittent dosing regimens. Studies in vitro 
and in animals, as well as a few clinical observations indicate that continuous infusion 
may be more efficacious than intermittent dosing. In the third part (Chapter 10), an in 
vitro pharmacokinetic model is described in which the pharmacodynamics of ceftazidime 
against Pseudomonas aeruginosa were studied during continuous and intermittent 
treatment regimens. 
Chapter 2 reviews the difficulties which may be encountered in antimicrobial treatment 
of CF patients. Two problems, abnormal pharmacokinetics and emergence of resistance 
respectively, are discussed in more detaiL 
CF patients display abnormal pharmacokinetics as compared to the general population. 
It has been observed in numerous studies that the elimination of various drugs, including 
some antibiotics, is enhanced in CF patients. The cause of this phenomenon, however, 
is not well understood, and may differ for individual drugs. Several mechanisms may be 
responsible, including increased metabolization and increased renal clearance, either 
passive or active. In addition, the body composition, the proportion fatty mass/free fatty 
mass or an anomalous circulating volume (first compartment) in relation to the total 
extracellular volume can also play a role. So-called 'deep' compartments are either 
known to exist or are speculated upon for several drugs. Another factor is the large inter-
and intra group variation within the CF patient population. This last issue has implicat-
ions for dosing regimens and is considered in more detail in Chapter 3, where individual 
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monitoring of antimicrobial agents is discussed with emphasis on CF patients. 
The second problem is the emergence of resistance against antimicrobial agents. In 
Chapter 4 the susceptibility to antibiotics of 52 Staphylococcus aureus isolates, isolated 
from 52 CF patients is descnoed. Forty-nine of the 52 isolates produced beta-lactamases, 
but methicillin resistant strains of S. aureus were not found. In general, MIC's of the 
drugs tested were within the therapeutic range. Since frequent antimicrobial treatment 
could lead to the emergence of tolerant strains, this was also studied. The frequency of 
tolerant strains found (11.2%), however, was not different from the frequency observed 
for the general population. 
In Chapter 5, the emergence of resistance among strains of P. aeruginosa isolated from 
34 chronically colonized CF patients was investigated by comparing in each patient the 
susceptibility for antibiotics in pairs of strains isolated before 1987 or after 1990. Strains 
isolated from a further 19 patients who had become newly colonized served as controls. 
There was a marked increase in resistance between the 34 pairs of isolates during the 
study period, which was not explained by a general increase over the 3-year interval, 
since strains isolated before 1987 exhibited similar susceptibilities as those cultured from 
the control group. There was a strong correlation between this increase and both the 
number of days in hospital and the frequency of admissions. Pattern analysis of the 
emergence of resistance indicated four separate groups comprising the fluoroquinolones 
except ofloxacin, the aminoglycosides, the ureidopenicillins together with aztreonarn, and 
the carbapenems, cephalosporins and carboxypenicillins as well as ofloxacin. It was 
concluded that long-term antimicrobial therapy is associated with the development of 
resistance within the individual patient. 
The problems encountered when treating CF patients with antibiotics, i.e. abnormal 
pharmacokinetics and emergence of resistance, infer that optimization of therapy is 
necessary. Except for the use of new antinticrobial agents, the employment of existing 
antibiotics can be improved. It is known, that killing of aerobic Gram-negatives by beta-
lactams continues in time and is relatively concentration independent. Continuous 
infusion of beta-lactams could, therefore, be more efficacious than the usual dosing 
regimen of three times daily when treating pulmonary exacerbations due toP. aeruginosa 
in CF patients. In the latter regimen, the high concentrations reached immediately after 
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infusion do not particularly contribute to efficacy, while after several hours concentra-
tions have fallen low enough to permit regrowth of the bacteria. Chapters 6-10 describe 
the pharmacokinetics of two beta-lactarns during continuous and intermittent infusion in 
a cross-over setting. The studies were performed in volunteers, CF patients and in vitro. 
The beta-lactarns ceftazidime and meropenem, a new carbapenem, were studied in 
volunteers. Apart from serum concentrations, the penetration in blister fluid was also 
analyzed. Blisters were obtained by applying negative pressure. It appeared that the 
concentration profile in the blisters was concurrent with that in serum, and that 
penetration was fast, although the concentrations in blister fluid were somewhat lower 
for both antibiotics. In the ceftazidime study, the effect of the age of the blister on the 
concentration profile was determined. This was done by taking samples from older 
blisters and comparing these concentrations with those obtained in younger blisters. It 
appeared that the concentration in suction blister fluid is dependent on the age of the 
blister, and that this factor should be taken into account when drawing conclusions from 
data obtained from suction blister fluid samples. During continuous infusion, there was 
no difference between ·concentrations found in older and younger blisters. 
The pharmacokinetics of ceftazidime during continuous and intermittent infusion was 
also studied in CF patients. The area under the time-concentration curve, total body 
clearance (TBC) and urinary recovery were not significantly different between the two 
treatment regimens, but these parameters showed a large variation not only between 
patients, but also within the same patient. The results were also compared with those 
observed in volunteers. During intermittent infusion, the half-lives were not significantly 
different, but the TBC was significantly higher and the volume of distribution was signifi-
cantly larger in the CF patients. During continuous administration, the serum con-
centrations were relatively lower in the CF patients, even if the higher lean body mass 
per kg bodyweight in the CF patients is taken into account. This could not be explained 
by a higher urinary clearance, since the urinary recovery was lower in the CF patients 
than in the volunteers. A comparison of the results of continuous and intermittent 
infusion showed that differences in the pharrnacokinetic parameters between volunteers 
and CF patients can be explained in part by a difference in volume of distribution. 
During the studies described above, it was noted that serum concentrations of both cef-
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tazidime and meropenem were significantly higher in the morning than in the evening; 
this circadian rhythm is described in Chapter 9. 
In Chapter 10, a model is described to simulate concentration profiles of antibiotics in 
vitro. The model was developed to study killing of P. aeruginosa during continuous and 
intermittent dosing in a dynamic situation. The results show that the model is useful to 
simulate in vivo concentration profiles, and that the model can be used to study bacterial 
killing in vitro. The efficacy of continuous and intermittent infusion ( q8h) of ceftazidime 
with a total daily dose of 300 mg/l/24h, mimicking human serum concentrations, was stu-
died over a period of 36 hours. Three P. aeruginosa strains, ATCC 27853, CF224 and 
CF224M were studied, with MICs of 1, 4 and 16 mg/1, respectively. The results showed 
that the efficacy of continuous infusion was higher for the strains with an MIC of 1 and 
4 mg/1. After the fourth dosing interval. i.e. after 32 hours, there was a marked dif-
ference between bacterial counts during continuous and intermittent infusion for these 
strains, 2.2 and 3.8 10log respectively. During both regimens, the strain with an MIC of 
16 mg/1 started to regrow after approximately 10 hours. This was due to the emergence 
of resistant strains with a higher MIC. Measurement of beta-lactamase in the medium 
revealed that, in most cases, this could be attributed to the emergence of beta-lactamase 
producing strains. However, beta-lactamase could not be detected during emergence of 
resistant subpopulations of strain CF224. 
The conclusion of the experiments was that, in the absence of other factors, a sustained 
level of ceftazidime around or slightly above the MIC is not high enough to maintain 
efficacy over more than one (8h) dosing interval, and should probably be around 4 to 5 
times the MIC. When sustained concentrations higher than 4 times the MIC are 
employed, continuous administration in this model is more efficacious than intermittent 
dosing. 
DIRECTIONS FOR FUTURE RESEARCH. 
The main problem when treating CF patients with antimicrobial agents, namely the 
emergence of resistant strains, is difficult to solve. Such is nature. However, the problem 
may be avoided, or at least the risk minimized by using antibiotics in a rational manner, 
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with care and only when required. The question that immediately rises is: when is the 
use of antimicrobial therapy really necessary? It cannot be denied that a pulmonary 
exacerbation needs antimicrobial treatment, and there are several parameters indicating 
when its use is mandatory. However, as noted in Chapter 2, during recent years new 
approaches to antimicrobial treatment are being used, such as intravenous treatment at 
home, and spraying with aerosolized antibiotics. In addition, antibiotics effective against 
P. aeruginosa which can be taken orally have become available. Furthermore, new ideas 
to prevent colonization with P. aeruginosa are becoming accepted. Although these 
approaches are probably effective on the short term few, if any, studies have been per-
formed to determine the long-term effects of these modes of treatment. It is necessary, 
therefore, to initiate such studies, or at least monitor emergence of resistance in such a 
way that conclusions regarding the importance of emerging resistance during non-
hospitalized antibiotic treatment can be made. 
As was indicated in the Introduction, optimization of existing therapy is one way of 
expan.ding therapeutic possibilities. In the studies presented in this thesis, several were 
based on the assumption that continuous infusion of beta-lactarns may be more ef-
ficacious than intermittent infusion. Although the studies in human volunteers showed 
that penetration of beta-lactarns in blister (interstitial) fluid is fast and concentrations 
only slightly less than in serunt, the concentration of antibiotics at the site of the P. 
aeruginosa infection is not known and might be lower. Also, it is not known what the 
influence of continuous or intermittent infusion would be at the site of those infections. 
If concentrations at the site of infection are dependent on factors other than diffusion 
alone, for instance presence of beta-lactamases, it could be that intermittent infusion 
leads to higher concentrations near the micro-organisnt, albeit for only a short period of 
time. Alternatively, a combination of continuous and intermittent infusion could be 
beneficial. Methods developed recently to study the site concentrations of antibiotics 
(Honeyboume and Baldwin, 1992) could help to shed more light on this issue. 
The results of the experiments in the in vitro model showed that continuous infusion was 
more efficacious than intermittent infusion for strains with an MIC 4 to 5 times lower 
than the concentration maintained during continuous infusion. However, the strain with 
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an MIC of 16 mg/1 started to regrow after 10 hours even though the concentration was 
maintained above 16 mg/1. This was due to the evolvement of resistant strains. However, 
the strain with an MIC of 4 mg/1 originally also showed increasing resistance, but did not 
grow. The reasons for this are not yet clear and elucidating this mechanism could help 
to understand what happens in vivo. For instance, from sputa of CF patients, resistant 
strains can often be isolated without apparent problems for the patient at the time of 
isolation. Although the .immune system and other factors play a role here as well, compa-
rable mechanisms as just described in vitro may be similarly important. In this context 
it is interesting that P. aeruginosa strains isolated from CF patients often not ouly grow 
slower than control strains, hut also often do not grow beyond 4 or 5 10log cfu/ml. It 
could be that factors in tbe medium, whether absent or present, inhibit growth. Alter-
natively, the cost for the bacterium to maintain its resistance could he too high to permit 
a higher growth rate. 
The model which was developed is suitable to study the effect of antibiotic combinations. 
For instance, the efficacy of antibiotics with different half-lives can be studied. It would 
also be interesting to study the efficacy of continuous or intermittent infusion with a 
beta-lactam and an aminoglycoside, or a quinolone. Still another option would be to 
study the timing of dosing when using two antimicrobial agents. There are some reports 
suggesting that the efficacy of a beta-lactam in combination with an aminoglycoside can 
be improved by optimization of the time period between the dosing of the two agents. 
Reports on the efficacy of continuous infusion in humans compared to intermittent 
administration are still scarce. Only two randomized clinical trials have compared the 
efficacy of beta-lactams during these two dosing regimens , but definite conclusions from 
these trials could not be made (Bodey et al., 1979; Lagast et al., 1983). In another study 
performed in humans, it was shown that the time above the MIC of the micro-organism 
to combat is a major determinant in the outcome of treatment (Schentag, 1991). Further 
clinical trials are needed to demonstrate the validity of continuous treatment with beta-
lactarns. It may then appear that equal efficacy of continuous and intermittent infusion 
may be obtained with relatively lower doses during continuous infusion. 
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SAMENVA'ITING 
Longinfecties vormen nog steeds de belangrijkste oorzaak van morbiditeit en mortaliteit 
bij patienten met cystische fibrose (CF). Ondanks het feit dat de behandelings-
mogelijkheden in de loop der jaren enorm zijn toegenomen, leidt de achteruitgang van 
de longfunctie, als gevolg van destructie van het longweefsel door infecties, uiteindelijk 
tot een vroegtijdige dood. Het doe! van de studies zoals die beschreven staan in dit 
proefschrift, is drieledig. In bet eerste dee! (hoofdstukken 2-5) wordt een overzicht 
gegeven van de infectie- en behandelingsproblematiek die een rol spelen bij de behan-
deling van de longinfecties van CF patienten. In bet tweede dee! (hoofdstukken 6-9) 
worden een aantal studies beschreven, die als uitgangspunt hadden dat, gezien de 
noodzaak tot optimale antimicrobiele therapie bij CF patienten, continue infusie van 
beta-lactarns wellicht een beter effect zouden kunnen hebben dan de tot op heden 
gebruikelijke drie- of vierdaagse dosering. In vitro en dierexperimentele studies, alsmede 
enkele anecdotische therapeutische resultaten bij patienten leken daarop te wijzen. In 
het laatste dee!, hoofdstnk 10, wordt een in vitro farmacokinetisch model beschreven, 
waarin de farmacodynamiek van ceftazidime ten opzicbte van Pseudomonas aeruginosa 
werd bestudeerd gedurende continue en iotermitterende infusie. 
In hoofdstnk 2 word! een algemeen overzicht gegeven van de behandeling van longin-
fecties van CF patienten. Verschillende problemen komen hier aan de orde en worden 
ter discussie gesteld. Twee vraagstukken, afwijkende farmacokinetiek en ontwikkeliogvan 
resistentie, worden nader toegelicht en deze vormen oak de basis van de drie daaropvol-
gende hoofdstukken. 
De farmacokinetiek bij CF patienten is afwijkend ten opzichte van de algemene popula-
tie. Uit vele studies is gebleken dat CF patienten een versnelde eliminatie vertonen van 
een aantal farmaca, waaronder verschillende antibiotica. Waaraan dit precies moet 
worden toegeschreven is niet goed bekend. Het zou zowel een verhoogde metabolisatie 
kunnen betreffen, als een verhoogde renale klaring, zowel passief als actief. Een afwij-
kende lichaarnssamenstelliog ten opzichte van niet CF patienten zou eveneens een rol 
kunnen spelen. Zowel een andere verhouding vet/vet vrije massa, als een andere ver-
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houding circulerend volume (eerste compartiment)/resterend volume (tweede compar-
timent) kunnen hierbij van belang zijn; ook zijn van een aantal middelen zogenaamde 
diepe compartimenten bekend of er wordt over gespeculeerd. Binnen de groep CF 
patienten bestaat er wat dat betreft ook een grate variatie. In hoofdstuk 3 wordt dit nog 
eens nader bescbouwd, waarbij tevens wordt ingegaan op de noodzaak tot 'individual 
monitoring' van de CF patient, juist vanwege de grate individuele spreiding. 
Het tweede vraagstuk is de ontwikkeling van resistentie tegen antibiotica. In boofdstuk 
4 word! de gevoeligbeid voor een aan tal antibiotica van 52 Staphylococcus aureus 
starnmen beschreven. Deze werden geisoleerd uit sputa van 52 CF patienten. Negenen-
veertig vand de 52 isolaten produceerden beta-lactamase, maar methicilline resistente 
starnmen werden niet gevonden. De MRCs van de geteste antibiotica lagen in bet 
algemeen binnen de therapeutiscbe grenzen. Tevens wordt bier bekeken of tolerantie een 
rol speelt bij CF patienten. Omdat frequente antimicrobiele therapie zou kunnen leiden 
tot een verboogde frequentie van voorkomen van tolerante stammen, werd dit ook 
bestudeerd. De frequentie van tolerante stammen die gevonden werd (11.2%) was ecbter 
niet afwijkend ten opzicbte van bevindingen bij de algemene populatie. 
In bet daaropvolgende boofdstuk 5 worden de resultaten beschreven van een studie 
waarin bet toenemen van isolatie van resistente P. aeruginosa stammen bestudeerd werd. 
Van 34 CF patienten werden van elke patient gepaarde P.aeruginosa isolaten, gei:soleerd 
voor 1987 of na 1990, uit bet sputum met elkaar vergeleken door ze te typeren en de 
gevoeligheid voor een aantal antibiotica te testen. De tussenliggende periode tussen de 
isolaten binnen elk paar was minimaal 3 jaar. Als controle groep fungeerde een groep 
van 19 patienten die pas recent waren gekoloniseerd met P. aeruginosa. Het bleek dat 
de resistentie van de stammen binnen elk van de 34 paren over de jaren sterk was 
toegenomen. Dit kon niet verklaard kon worden door een algemene toename in resisten-
tie, omdat de stammen van de controle groep in bet algemeen eenzelfde resistentie 
patroon lieten zien als de 34 stammen gei:soleerd voor 1987. Er was een goede correlatie 
tussen de toename in resistentie en bet aantal opnames in bet ziekenhuis. Deze laatste 
kan als maat worden gezien van bet aantal malen dat intraveneuze therapie aan de 
patient gegeven is. Patroon analyse van de toename in resistentie liet vier groepen zien, 
bestaande uit de fluoroquinolonen bebalve ofloxacin, de aminoglycosiden, de ureidopeni-
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cillinen samen met aztreonam en tenslotte de carbapenems, cefalosporines, carboxypeni-
cillines en ofloxacin. 
Naar aanleiding van bovengeschetste problematiek, i.e. een afwijkende farmacokinetiek 
bij CF patienten en een toename van resistentie van de bacterien, is bet dnidelijk dat 
een optimale antimicrobiele therapie veelal noodzakelijk is. Bebalve de toepassing van 
nieuwe middelen kan tevens gezocbt worden naar de meest optimale toedieningsvorm 
van een antibioticum. Van beta-lactams is bekend dat de doding van Gram-negatieven 
door deze middelen doorgaat in de tijd en relatief concentratie onafhankelijk is, mits 
hoven een bepaald minimum. Het zou daarom zinvol kunnen zijn beta-lactams in een 
continu infuus toe te dienen, in tegenstelling tot de gebruikelijke drie daagse dosering, 
waarbij boge topspiegels geen extra effect bewerkstelligen, en anderzijds de spiegel na 
een aantal uren zodanig is gedaald dat geen effect meer optreedt. De smdies in de 
overige boofdsmkken bescbrijven de farmacokinetiek van enkele beta-lactams gedurende 
continue en intermitterende toediening bij de zelfde dagdosis in een cross-over setting. 
De smdies werden uitgevoerd bij vrijwilligers, CF patienten en in vitro. 
Bij vrijwilligers werden de beta-lactams ceftazidime en meropenem besmdeerd, waarvan 
de resultaten beschreven staan in hoofdsmk 6 en 7. Meropenem, een carbapenem, is een 
nieuw antibioticum met een goede antipseudomonale activiteit. Om tevens een indruk 
te verkrijgen van bereikte weefselconcentraties van deze middelen, werden blaren 
opgewekt door middel van negatieve druk, en de concentraties in de blaarvloeistof 
gemeten. Het bleek dat bet concentratie verloop in de blaarvloeistof goed overeenkwam 
met die in bet bloed, en er een snel evenwicht ontstaat. Zowel bij ceftazidime als bij 
meropenem werden iets lagere spiegels in de blaren aangetroffen. In de ceftazidime 
smdie werd tevens gekeken of de ouderdom van de blaar van invloed was op de gemeten 
spiegels. Dit werd gedaan door van oudere blaren monsters te trekken en de con-
centraties daarin te vergelijken met die van jongere blaren. Het bleek dat de ouderdom 
van de blaar inderdaad van invloed is op de gemeten concentratie bij intermitterende 
toediening. De conclusie was, dat dit soon blaren, a1s ze een indruk willen geven van de 
concentratie in bet weefsel, steeds nieuw getrokken moeten worden. Bij continue infusie 
werd geen verschil in concentratie aangetoond mssen oude en jongere blaren. 
De farmacokinetiek van ceftazidime gedurende continue en intermitterende infusie werd 
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tevens bestudeerd in CF patienten (hoofdstuk 8). De oppervlakte onder de tijd con-
centratie curve, de totale lichaamsklaring (TBC) en terugvondst in urine waren niet 
significant verschillend tussen de twee behandelingsschema's, maar er was een grate 
intra-individuele als ookinter-individuele spreiding. De resultaten werden ookvergeleken 
met die van de vrijwilligers. Er was geen kortere halfwaardetijd, maar zowel het ver-
delingsvolume als de klaringwaren signifikant hager bij de CF patienten tijdens intermit-
terende toediening. Gedurende continue toediening waren de serum concentraties 
relatief lager in de CF patienten, ook als de relatief hogere verhouding Lean Body 
Mass/kg lichaamsgewicht daar in betrokken werd. Een vergelijking tussen continue en 
intermitterende infusie liet zien, dat een dee! van gevonden verschillen van far-
macokinetische parameters tijdens intermitterende infusie bij vrijwilligers en CF patien-
ten verklaard kan worden door een verschil in verdelingsvolume. 
In hoofdstuk 9 worden enkele bevindingen beschreven naar aauleiding van de hiervoor 
beschreven studies. Er werd gesignaleerd dat zowel de ceftazidime als de meropenem 
serum concentraties 's ochtends relatief hoger waren dan 's avonds. Hoewel het hier een 
beschrijving van een fenomeen gaat, kan geen uitspraak worden gedaan over de oorzaak 
van dit circadiaanse ritrne. 
Werden in het voorgaande continue en intermitterende infusie in vivo bestudeerd, in 
hoofdstuk 10 wordt een model beschreven waarmee het mogelijk is om het spiegelver-
loop van intermitterende en continue infusie in vitro na te bootsen. Het model werd 
opgezet met de bedoeling om de doding van bacterien te kunnen bestuderen onder een 
dynamisch verlopende spiegel, in tegenstelling tot de statische spiegel zoals die gehan-
teerd wordt in MRC bepalingen en killing-curves. Met het uiteindelijke model konden 
spiegelverlopen goed reproduceerbaar nagebootst worden. Het model werd vervolgens 
gebruikt om de doding van verschillende P. aeruginosa Stammen te bestuderen tijdens 
continue en intermitterende infusie (q8h) van ceftazidime gedurende 36 uur in een 
dosering van 300 mg/l/24h. Dit resulteerde in een concentratie verloop van ceftazidime 
dat vergelijkbaarwas met dat wat met adequate therapie gemeten wordt. De bestudeerde 
P. aeruginosa stammen ATCC 27853, CF224 and CF224M hadden een MRC voor cefta-
zidime van respectievelijk 1, 4 en 16 mg/L Het bleek, dat de doding van P. aeruginosa 
tijdens continue infusie effectiever was dan bij intermitterende infusie voor de stammen 
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met een MRC van 1 en 4 mgjl bij dezelfde dagdosis. Het verschil na vier doseringen, 
i.e. na 32 uur, bedroeg uitgedrukt in verschil in concentraties bacterien respectievelijk 
2.2 en 3.8 1"log. De starn met een MRC van 16 mg/1 hergroeide echter na 10 uur 
gedurende heide regimes. Dit bleek in beide regimes om een beta-lactamase vormende 
mutant te gaan. Beta-lactamase kon echter niet aangetoond worden gedurende het 
optreden van resistente sub-populaties van starn CF224. De niteindelijke conclusie was, 
dat een continue spiegel ter hoogte of iets boven de MRC in dit model niet voldoende 
was, en een effectieve spiegel ongeveer een factor 4 tot 5 daar boven ligt. De resultaten 
met dit model toonden ook dat een of twee doserings intervallen te kort is om een effect 
goed te beoordelen. 
149 
LIST OF PUBLICATIONS 
Schaik van CP, Amerongen van A and Mouton JW. The organisation of range use in Sumatran long-
tailed macaques. In Schaik, CP van: The socioecology of Sumatran long-tailed macaques (Macaca 
fascicularis). 23-65, 1985 
Mouton JW and Kerrebijn KF. AnUOacterial therapy in cystic fibrosis. Med C1in North Am 74:837-850, 
1990 
Daal van GJ, Jong dePT, Tenbrlnck R, Mouton JW, Petzoldt K, Bergmann KC and Lachmann B. Oral 
immunization with bacteria! lysate against infection with Streptococcus pneumoniae in mice. Respiration 
57:129-'132, 1990. 
Mouton JW, Horrevorts AM, Mulder PGH, Prens EP and Michel MF. Pharmacokinetics of ceftazidime 
in serum and suction blister fluid during continuous and intermittent infusion in healthy volunteers. 
Antimicrob Agents Chemother 34:2307-2311, 1990 
Daal van GJ, So KL, Mouton JW, Veen van 't ~ Tenbrinck R, Bergmann KC and Lachmann B. Oral 
immunization with a polyvalent bacterial lysate can reduce mortality by infection with S. pneumoniae or 
Influenza A in mice. Pneumologie 44:1180-1182, 1990 
Kerrebijn KF and Mouton JW. Pulmonary infection and antJ.Oiotic treatment in patients with cystic 
fibrosis. Acta Univ Carol36:28-33. 1990 
Daal van GJ, Beusenberg FD, So KL. Fievez RBAM, Sprenger MJW. Mouton JW, Veen van't A and 
Lachmann B. Protection against influenza A virus infection in mice by oral immunization with a 
bacterial lysate. Int J Immunopharmac 13:831-840, 1991 
Horrevorts AM and Mouton JW. Suscepll"bility to various antimicrobial agents and tolerance to 
methicillin of Staphylococcus aureus isolates from cystic fibrosis patients. Eur J Clin Microbial Infect 
Dis 10:785-786, 1991 
Kluytmans JAJW, Niesters HGM, Mouton JW, Quint WGV, Jjpelaar JAJ, Rijsoort-Vos JH, Habbema L, 
Stolz E, Michel MF and Wagenvoort JHT. Performance of a non-isotopic DNA-probe for detection of 
Chlamydia trachomatis in urogenital specimens. J Clin Microbio129:2685-2689, 1991 
Mouton JW and Michel MF. Pharmacokinetics of meropenem in serum and suction blister fluid during 
continuous and intermittent infusion. J Antimicrob Chemother 28:911-918, 1991 
Horrevorts AM, Mouton JW, Driessen OMJ and Kerrebijn KF. Pharmacokinetische en 
phannacodynamische studies bij patienten en vrij-.vill.igers. In: Ontwikkelingen in de behandeling van 
infectieziekten (Bakker-Woudenberg WM, Horrevorts AM: eds.), 34-51, 1991 
150 
Daal van GJ, Veen van 't ~ So KL, Mouton JW, Smit F, Hal van PthW, Bergmann KC and Lachmann 
B. Oral immunization with polyvalentlysate and infection with S. pneumoniae: influence on interferon-
gamma and PMN-elastase concentrations in murine bronchoalveolar lavage fluid. Int Arch Allergy 
lmmunol 97:173-177, 1992 
Mouton JW and Michel MF. Meropenem pharmacokinetics in serum and suction blister fluid during 
continuous and intermittent infusion. In: Proceedings ICC "Recent advances in chemotherapy". (Lode 
H, Adam D eds.) Futuramed verlag, Munchen, 1()66..1067, 1992 
Mouton JW, Horrevorts AM and Michel MF. Circadian rhythm of ceftazidime and meropenem serum 
levels during continuous and intermittent infusion. In: Proceedings ICC "Recent advances in 
chemotherapy". (Lode H, Adam D eds.) Futuramed verlag, Munchen, 1016-1017, 1992 
Teunenbroek van A, Muinck Keizer-$chrama de SMPF, Stijnen T, Mouton JW, Blum WF, Mercado ~ 
Baumann G, Drop SIS and the Dutch Working Group on Growth Hormone. Effect of growth 
hormone administration frequency on 24h growth hormone proflles and levels of other growth related 
parameters in girls with Turner"s syndrome. Clin Endocrinol 39:77-84, 1993. 
Horrevorts AM and Mouton JW. Abnormal pharmacokinetics: the need for monitoring. Eur J Clin 
Microbiollnfect Dis 28(Suppl):58-60, 1993 
Vos MC, Vmcent HH, Yzerman EPF, Stamkott A, Vogel M and Mouton JW. Drug clearance by 
continuos hemodiaftltration (CA VHD). II. Results with the AN-69 capillary hemofilter and 
recommended dose adjustments. submitted. 
Veeze HJ, Mouton JW, Halley DJJ, Overbeek. SE, Jongste de J and Sinaasappel M. Clinical variability in 
patients with cystic fibrosis who are non-homozygous for the most common CF mutation. submitted. 
Mouton JW, den Hollander JG and Horrevorts AM. Emergence of resistance among Pseudomonas 
aeruginosa isolated from cystic fibrosis patients. J Antimicrob Chemother 31:919-926, 1993 
Mouton JW, Horrevorts AM, Overbeek SE, Kerrrebijn KF and Michel MF. Pharmacokinetics of 
ceftazidime during continuous and intermittent infusion in adult cystic fibrosis patients. submitted. 
Mouton JW, Horrevorts AM and Michel MF. Circadian variation in serum concentrations of ceftazidime 
and meropenem. submitted. 
Eijldng EP, Gommers D, So KL, Maat de MPM, Mouton JW and Lacbmann B. Prevention of 
respiratory failure after hydrochloric acid aspiration by intratracheal surfactant instillation in rats. 
Anesth Analg 76:472-477, 1993 
Bakker-Woudenberg IAJM, Lokerse AF, Kate ten MT, Mouton JW, Woodle MC and Storm G. 
Liposomes with prolonged blood circulation and selective localization in Klebsiella pneumoniae infected 
lung tissue. J Infect Dis 168:164-171, 1993. 
151 
Bakker W, Vmks AATMM, Mouton JW, de Jonge P, Verzijl JG en Heijerman HGM. Intraveneuze 
thuis-behandeling bij patienten met cystic fibrosis: continue infusie van ceftazidim via een draagbare 
pomp. geaccepteerd. 
Mouton JW en Vmks AATMM. De antimicrobiele behandeling met beta-lactam antibiotica: is continue 
infusie zinvol? geaccepteerd. 
Kluytmans JAJW, Goessens WHF, Mouton JW, Rijsoort-Vos JH, Niesters HGM, Quint WGV, 
Habbema L, Stolz E and Wagenvoort JHT. Evaluation of the clearview chlamydia test, the magic lite 
chlamydia test, a polymefase chain reaction and cell culture for detection of Chlamydia trachomatis in 
urogenital specimens. submitted. 
Veen van 't A, Ruyter de HA, Mouton JW, Hartleb M and Lachmann B. Pretreatment with spleenextract 
enhances survival in influenza A infected mice. submitted. 
Goessens WHF, Deventer van A.JM, Zeijl van JH, Mouton JW and Michel MF. Discriminative antlOody 
and antigen reactions in immunocompromised patients with systemic candidiasis. submitted. 
Mouton JW and Hollander den JG. Killing of Pseudomonas aeroginosa during continuous and 
intermittent infusion of ceftazidime in an in vitro phannacokineric model. submitted. 
152 
DANKWOORD 
Mijn dank gaat uit naar een ieder die een bijdrage heeft geleverd aan de totstandkoming 
van dit proefschrift. 
Mijn promotor Prof. dr. M.F. Michel dank ik voor de gelegenheid die hij mij heeft 
geboden om onderzoek te doen, en de vrijbeid die hij mij daarin gelaten beef!. De 
bereidheid om altijd te luisteren en binnen te kunnen vallen ( op soms ongelegen 
momenten) zijn van groot belang geweest voor de totstandkoming van dit proefschrift. 
Mijn tweede promotor Prof. dr. K.F. Kerrebijn wil ik danken voor de wijze waarop hij 
mij betrokken beeft bij bet kliuische onderzoek. Ook zijn Stelling, bij de aanvang van het 
onderzoek 'elke onderzoeker moet een computer hebben' is voor mij vao grote betekeuis 
geweest. 
Mijn copromoter dr. AM. Horrevorts dank ik voor de vele inspirerende maar ook 
gezellige discussies. Beste Alphons, als het nodig was hielp je me weer even op het 
rechte pad. Met jou en Shelley op reis is een aparte beleveuis. 
De overige leden vao de leescommissie, Prof. dr. C. Hilvering en Prof. dr. D.D. Breimer 
dank ik voor het doorlezen vao het manuscript. 
Shelley Overbeek, zonder jou waren een aantal hoofdstukken in dit boekje nooit 
geschreven. 
Jan den Hollander wil ik bedanken voor zijn bijzondere inzet en de bijdrage die hij heeft 
geleverd voor een aantal studies. 
Paul Mulder dank ik voor zijn altijd heldere uitleg als het voor mij even minder helder 
was. Errol Prens heeft mij de techniek vao het blaren trekken bijgebracht. Marins Vogel 
bracht mij de kneepjes vao de HPLC bij en Willem vao Leeuwen de pseudomonas 
typeringen. Don Poldennans hield de veiligheid van de vrijwilligers in het oog. Laraine 
Visser corrigeerde het engels. 
De betrokkenen op de longafdeling SKZ , Dijkzigt en Interne IT dank ik voor de 
gastvrijheid en medewerking. De medewerkers op het bacteriologisch laboratorium dank 
ik allen voor hun betrokkenheid. De stagiaires Karin van Steenhoven en Susanne 
Verhoeven dank ik voor de experimenten die zij gedaan hebben. 
Wi! Goessens, Irma Bakker en de andere onderzoekers op de 1'7' dank ik voor hun 
153 
bijdrage in de vele discussies. 
Mijn (ex)collega's op de afdeling bacteriologie Jan Kluytmans, Ed Ijzerman, Jan van 
Zeyl, Eliane Thewissen, Huben Endtz, Hans Wagenvoort, Siem de Marie, Inge Gijssens 
en Gardena Dzjolic dank ik voor hun betrokkenheid bij de totstandkoming van dit 
boekje. 
Jan en Ed waren bereid om mij, behalve tijdens onze 'wetenschappelijke edoch sportieve 
excursies' ook bij te staao in het laatste uur. 
Gen-Jan van Daal, Erik Eijking, Arthur Voogd, Jelle Bos, Greet Vos, Annemarie van 
't V een, Diederik Gammers, Wim Bakker, Harry Heyerman, Alexander Vinks en vele 
anderen zorgden voor gezelligheid, zinnige en onzinnige discussies. 
Mijn ouders dank ik voor alles. 
En Carla. 
154 
CURRICULUM VITAE 
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werd het doctoraalexamen biologie behaald, met als hoofdvakken microbiele genetica 
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Het doctoraalexamen Geneeskunde werd behaald in 1986 en het artsexamen in 1988. In 
april 1988 trad hij als AIO in dienst vao de Erasmus Universiteit te Rotterdam, alwaar 
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van Prof. dr. M.F. Michel, Prof. dr. KF. Kerrebijn en dr. AM. Horrevorts. In aprill990 
werd de opleiding tot Medisch Microbioloog aaogevangen aao het Dijkzigt ziekenhuis 
te Rotterdam. 


